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ABSTRACT
Longer life expectancies, due to advanced medical care, social, and
environmental conditions, helped increase the number and percentage of
Americans aging to ≥85. The number of individuals with Alzheimer’s disease
(AD) age 65 or older is projected to be 7.1 and 13.8 million by 2025 and 2050,
respectively. The total annual health care expense for AD patients is estimated to
increase from $290 billion in 2019 to more than $1.1 trillion in 2050 (Association,
2019). Conclusively, AD is expected to become a more common cause of death
and a major public health predicament due to aging of the baby boom generation
in the United States.
Extracellular Aβ plaque deposition resulting from successive proteolytic
cleavage of amyloid precursor protein (APP), intracellular neurofibrillary tangles,
and neuroinflammation are pathophysiologic features of AD correlating with
cognitive decline, language impairment, memory loss, and ultimately, death. Due
to the behavioral manifestation and the neurodegenerative hallmarks, AD is
typically considered a brain specific disease. However, peripheral inflammatory
changes such as increased serum levels of TNF-α, worsen cognitive decline in
AD patients. This suggests that systemic inflammatory changes may cross-talk to
the brain to influence disease. In support of this idea, long-term use of nonsteroidal anti-inflammatory drugs (NSAID) decreases the risk of AD. Interestingly,
xviii

colitis and colitis-associated colorectal cancer (CAC), which are characterized by
accelerated levels of proinflammatory cytokines, induce anxiety, depression and
cognitive/memory dysfunction in preclinical and clinical studies. Taken together,
these studies suggest that peripheral immune changes influence AD progression
in the brain.
This dissertation consists of three related but separate studies aimed at
understanding the impact of peripheral manipulations on brain pathology using
AD mouse models. In our first study, we asked whether the liver-derived
hormone, insulin like growth factor-1 (IGF-1), has effects in the brain to potentiate
or attenuate disease using the AβPP/PS1 mutant mouse model of AD. To test
this idea, we used a brain penetrant IGF-1R inhibitor. The second study shifts to
focus on peripheral inflammatory manipulations to examine possible influences
on disease. This study utilized a common colitis-like model of oral dextran sulfate
sodium (DSS) to quantify brain and intestinal changes in the AppNL-G-F mutant
knock-in mouse model of AD. The third study employed a more extensive
intestinal inflammatory paradigm of colorectal tumorigenesis to also compare
brain and intestinal changes using the AppNL-G-F mice.
In the first study, the brain penetrant IGF-1R inhibitor (PPP, 1mg/kg/day)
attenuated insoluble Aβ1-40/42 and pro-inflammatory cytokine levels (eotaxin, TNFα, IL-1α, and IL-1β) in the temporal cortices of AβPP/PS1 mice. Additionally, an
attenuation in microgliosis and protein p-tyrosine levels was observed due to
drug treatment. Our data suggests IGF-1R signaling is associated with disease
progression in this mouse model. More importantly, modulation of the brain IGFxix

1R signaling pathway was sufficient to attenuate aspects of disease phenotype.
This suggested that small molecule therapy targeting liver-derived IGF-1 effects
in the brain may be a viable intervention approach.
In the second study, chronic intestinal inflammation, induced by dissolving
2% dextran sulfate sodium (DSS) in the drinking water, resulted in bloody
diarrhea, disrupted colonic epithelium, and weight loss in wild type and AppNL-GF

male mice, changes similar to human inflammatory bowel disease (IBD). The

inflammation correlated with increased levels of brain insoluble Aβ1-40/42 and
decreased microglial CD68 immunoreactivity in DSS treated compared to vehicle
treated AppNL-G-F mice. These data demonstrated that intestinal dysfunction is
capable of altering plaque deposition and immune cell behavior in the brain. This
study increased our understanding of the impact of peripheral inflammation on
Aβ deposition and neuroinflammation in AD via an IBD-like model system.
In the third study, azoxymethane (AOM)/DSS administration produced
genotype and sex dependent colitis-associated colorectal cancer (CAC)
symptomatic parameters in spleens and colons of wild type, App-/-, and AppNL-G-F
mice. As expected, AOM/DSS treatment exacerbated Aβ plaque load in male
AppNL-G-F mice. Interestingly, AOM/DSS treated male AppNL-G-F mice also
demonstrated worsened intestinal inflammation and increased colonic
tumorigenesis compared to wild types. However, AppNL-G-F female mice were
protected against intestinal inflammation and tumorigenesis as well as any
exacerbation of brain Aβ plaque load. These data demonstrated that the ADassociated autosomal dominant mutations of APP introduced into the AppNL-G-F
xx

mouse line provide protection against intestinal disease as well as brain
exacerbation in a sex-selective fashion.
Collectively, studies in this dissertation demonstrate that peripheral stimuli,
whether hormonal or inflammatory, appear capable of altering disease phenotype
in two commonly used mouse models of AD. In addition, there may be sexselectivity of this peripheral to brain communication during disease. One
conclusion from this work is that manipulations of peripheral events may be
sufficient to alleviate brain changes in AD. This suggests the exciting possibility
that therapeutic interventions need not penetrate into the brain to offer benefit.

xxi

CHAPTER I
INTRODUCTION
Dissertation Research Objectives and Organization
Chapter I introduces AD and its pathological characteristics in the brain,
the importance of growth factor contribution to disease progression, the gut-brain
axis and its relevance to AD, and a possible relationship between AD and gut
dysfunction associated with colitis and CAC. Chapter II elaborates our initial
effort to determine whether manipulating brain effects of a peripheral signal,
IGF-1, could affect plaque deposition and neuroinflammation using an IGF-1R
inhibitor and the AβPP/PS1 mouse model of AD. Based upon the success of this
intervention, we elected to move away from growth factor interventions and focus
instead on understanding whether peripheral inflammatory conditions contributed
to brain changes during disease. Chapter III describes our effort to develop the
necessary Swiss-roll protocol to study mouse colons histologically. Chapter IV
summarizes results obtained using a mouse DSS model of colitis to verify that
intestinal dysfunction and inflammation propagates to the brain using the
AppNL-G-F mouse model of AD. Chapter V continues assessing colonic
inflammation through an AOM/DSS colonic tumorigenesis model to demonstrate
that mutant APP expression exacerbates tumorigenesis and Aβ plaque
deposition in male AppNL-G-F mice but serves a protective function against both
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tumor development and plaque exacerbation in female AppNL-G-F mice. The
results of all three studies are discussed in detail in Chapter VI.
Alzheimer’s Disease (AD) Discovery and Overview
A 51-year-old woman, Auguste D., was hospitalized in the Frankfurt
Community Psychiatric Hospital due to an untreatable paranoid symptomatology
followed by a progressive, intensive, and deteriorative sleep disorder, memory
disturbances, aggressiveness, crying, and confusion in November 1901. During
his senior assistantship at the hospital, Dr. Alois Alzheimer, accurately recorded
Auguste’s course of disease development and progression until her death on
April 8, 1906. The morphological and histological study of her postmortem brain
revealed alterations which later would be called plaques and neurofibrillary
tangles. This peculiar, severe disease process of the cerebral cortex was
reported for the 1st time by Alois Alzheimer at the 37th meeting of South-West
German Psychiatrists on November 3, 1906 in Tubingen. Later in 1910, Emil
Kraepelin, Alzheimer’s colleague, included Dr. Alzheimer’s case study on
Auguste D. in his 8th edition of Psychiatrie textbook and introduced this disorder
as Alzheimer’s disease (Alzheimer, Stelzmann, Schnitzlein, & Murtagh, 1995;
Hippius & Neundörfer, 2003).
In 1984, amyloid protein was first sequenced from the meningeal blood
vessels of AD patients by Glenner and Wong. In the same year, they reported
the chemical relationship between Down’s syndrome (DS) and AD due to the
homology of the sequenced cerebrovascular amyloid protein isolated from an
adult DS patient and the one from AD, suggesting localization of the genetic
2

abnormality to chromosome 21 (Glenner & Wong, 1984a, 1984b). A year later,
the 40 residue amyloid protein (4 kDa) was isolated from the plaque core of both
AD and aged DS brains (Masters et al., 1985). In 1987, Kang and colleagues
discovered that the same highly aggregating amyloid protein (A4), purified from
blood and cerebral plaque deposits of AD and DS patients, has a neuronal origin
and is cleaved from a larger precursor protein containing 695 residues. The
β-amyloid precursor protein A4 (APP) is located on chromosome 21 and
resembles glycosylated cell surface receptors (Kang et al., 1987). Shortly
afterwards, pathogenic mutations were identified in the APP gene which resulted
in the upregulation of Aβ production in familial early-onset AD (X. D. Cai, Golde,
& Younkin, 1993; Citron et al., 1992; Goate et al., 1991; Hendriks et al., 1992;
Mullan et al., 1992; Suzuki et al., 1994; Wisniewski, Ghiso, & Frangione, 1991).
Based upon these discoveries, the amyloid cascade hypothesis was formulated
and described amyloid-beta (Aβ) aggregation as an initial phenomenon in AD
pathogenesis. In this hypothesis, neurofibrillary tangles (NFTs), neuronal death,
synaptic loss, vascular damage, and subsequent dementia all occur due to
Aβ deposition (Hardy & Higgins, 1992).
APP Family
The human APP gene is a single-pass transmembrane protein containing
18 exons and contributes to neuronal development, signaling, intracellular
transport, iron export, and homeostasis (G. F. Chen et al., 2017; Kang et al.,
1987). It is located on chromosome 21 and belongs to the APP family of proteins.
Besides APP, the APP family also includes APP-like protein 1 and 2 (APLP1 and
3

APLP2) in which the Aβ sequence is missing at the C-terminal end. APP family
members consist of a long and diverse extracellular N-terminus and a short
cytoplasmic C-terminus (Sprecher et al., 1993; Wasco et al., 1993). The APP
gene undergoes alternative splicing to create isoforms with different amino acid
lengths, including APP639, APP695, APP714, APP770, and APP751 (Golde,
Estus, Usiak, Younkin, & Younkin, 1990; K. L. Puig & Combs, 2013; Tang et al.,
2003). Structurally, the dimerization domains (E1 and E2), which bind heparin,
zinc, and copper to form homo- or heterodimers, and acidic domain (Ac) are
common in extracellular regions of APP family proteins, including APP695 and
APLP1. APP751 contains a Kunitz protease inhibitor (KPI) domain in exon 7.
Whereas, APP770 and APLP2, additional to the KPI domain, also carry an Ox-2
antigen (OX2) domain located in exon 8. Although APP695 and APLP1 are
chiefly expressed in the brain, other APP isoforms and APLP2 are ubiquitously
expressed in multiple organs throughout the body (Nalivaeva & Turner, 2013;
van der Kant & Goldstein, 2015).
APP Processing
Missense mutations in the APP gene, which promote APP cleavage by βsite APP-cleaving enzyme 1 (BACE1) in secretory vesicles, as well as mutations
in γ-secretase subunit (presenilin, PSEN1 and PSEN2) genes lead to
overproduction and secretion of Aβ in familial early-onset AD (EOAD). EOAD
occurs before age 65 and accounts for about 5% of patients (Awada, 2015;
Haass et al., 1995). Impaired Aβ clearance mediated by apolipoprotein E
(APOEε4) is considered a primary pathologic event in sporadic late-onset AD
4

(LOAD), which accounts for almost 95% of all AD cases (Corder et al., 1993;
Strittmatter et al., 1993; Yamazaki, Painter, Bu, & Kanekiyo, 2016).
Like other transmembrane proteins, APP translation occurs in the
endoplasmic reticulum. The newly synthesized protein is transported to the trans
Golgi network apparatus for posttranslational modifications and subsequently
trafficked to the cell surface membrane via the secretory pathway (Greenfield et
al., 1999; Walter & Haass, 2000). APP is processed by two distinct pathways,
including the amyloidogenic APP processing pathway and non-amyloidogenic
APP processing pathway. Different APP posttranslational modifications, i.e. Nand O-linked glycosylation, phosphorylation, ubiquitination, and tyrosine
sulfations, may cause this transmembrane protein to favor one pathway over
another. With a highly conserved YENPTY motif in the intracellular C-terminal
end, APP binds to different intracellular adaptors, i.e. APP-binding family A
(APBA or MINT) members and APP-binding family B member 1 (APBB1 or
FE65), for various cytosolic trafficking and delivery to proteases (Agostinho,
Pliassova, Oliveira, & Cunha, 2015; Jiang et al., 2014; King & Scott Turner,
2004).
In the amyloidogenic pathway, an intracellular adaptor protein, FE65,
(APBB1) via its two distinct phosphotyrosine-binding (PTB) domains, binds to the
NPXY (from a larger motif YENPTY) motifs presented in the C-terminus of both
APP and Low-density lipoprotein receptor (LDLR)-related protein 1 (LRP1) (Fig.
I-1A and C). This intracellular interaction results in rapid clathrin-mediated
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Figure I- 1.

APP amyloidogenic and non- amyloidogenic processing
pathways.
A) In the amyloidogenic pathway, (1) binding of FE65 to the
NPXY C-terminal motifs of APP and LRP1 (2) triggers a rapid
clathrin-mediated internalization of APP. (3) In the acidic milieu
of endosome (pH 4.5), APP is cleaved by β-secretase BACE1 to
generate luminal sAPPβ and endosomal membrane-bound C99.
(4) C99 is further processed by γ-secretase to release Aβ
peptide and AICD fragments into the endosomal lumen and
cytoplasm, respectively. (5) Mostly, sAPPβ and Aβ are recycled
to the plasma membrane and exocytosed. Secreted Aβ
monomers self-aggregate to form oligomers, protofibrils,
insoluble fibrils, and subsequent Aβ plaques. (6) AICD is
translocated into the nucleus to function as a transcription factor.
B) In the non-amyloidogenic pathway, (1) APP is retained at the
cell surface where it is cleaved within the Aβ sequence by αsecretase to (2) release the extracellular sAPPα and produce a
cell membrane-bound C83. (3) Following endocytosis, (4) C83 is
cleaved by γ-secretase to generate luminal P3 and cytoplasmic
AICD fragments. (5) P3 is secreted extracellularly and (6) AICD
is translocated to nucleus, finally.
C) Summary of APP amyloidogenic and non-amyloidogenic
processing pathways. APP, amyloid precursor protein; FE65
(APBB1), APP-binding family B member 1; LRP1, Low-density
lipoprotein receptor (LDLR)-related protein 1; sAPPβ, soluble
APPβ; C99 (CTFβ), membrane-bound C-terminal fragment-β;
AICD, APP intracellular domain; sAPPα, soluble sAPPα; C83
(CTFα), membrane-bound C-terminal fragment-α. Created with
Biorender.com.
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endocytic trafficking of APP (Cam, Zerbinatti, Li, & Bu, 2005; Nordstedt,
Caporaso, Thyberg, Gandy, & Greengard, 1993; Pietrzik et al., 2004;
Trommsdorff, Borg, Margolis, & Herz, 1998; F. Wu & Yao, 2009). Plasma
membrane milieu (pH 7.5) is not optimal for β-secretase BACE1 activity.
Subsequently, APP is cleaved by BACE1, which is activated in the acidic milieu
of endosomes (pH 4.5), to release soluble APPβ (sAPPβ) in the endosomal
lumen. Although it can be degraded by merging with lysosomes, sAPPβ is also
recycled toward the cell surface membrane and exocytosed. The membranebound C-terminal fragment-β (CTFβ also known as C99) in the endosomal
membrane is then processed by γ-secretase to generate a hydrophobic 37 to 49
amino acid Aβ peptide (4kDa) which can be secreted into the extracellular milieu
via exosomes. Almost 90% of γ-secretase product is soluble Aβ40 with the
remaining portion as highly fibrillogenic Aβ42 and Aβ43 peptides which are often
deposited in amyloid plaque cores. Upon γ-secretase cleavage, the APP
intracellular domain (AICD) is released to the cytoplasm and translocated to the
nucleus as a transcription factor (Cole & Vassar, 2007; De Strooper, 2003;
Hussain et al., 1999; Konietzko, 2012; Lin et al., 2000; Nunan & Small, 2000;
Rajendran et al., 2006; Sinha et al., 1999; Sisodia & St George-Hyslop, 2002;
Thinakaran & Koo, 2008; Van Gool et al., 2019; Vassar et al., 1999; Yan et al.,
1999). Secreted Aβ monomers, mostly Aβ40 and Aβ42, spontaneously selfaggregate to form soluble oligomers, protofibrils, insoluble larger fibrils, and
amyloid plaques which are hypothesized to subsequently lead to disruption of
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normal brain architecture, neuronal degeneration, and cognitive impairment in
AD (Glenner & Wong, 1984b; Graham, Bonito-Oliva, & Sakmar, 2017).
Due to its slow rate of endocytosis, LRP1B association with APP is known
to retain APP at the plasma membrane and promote the non-amyloidogenic
pathway of metabolism (Cam et al., 2004). In this mechanism, APP is initially
cleaved by α-secretase at the plasma membrane within the Aβ sequence
(between amino acid 16 and 17) to extracellularly liberate a soluble APPα
(sAPPα) ectodomain and to produce a membrane-bound C-terminal fragmentα (CTFα also known as C83). CTFα is endocytosed and further cleaved by γsecretase to produce P3 (3 kDa) and ACID fragments (Golde, Estus, Younkin,
Selkoe, & Younkin, 1992; Haass & Selkoe, 1993; Sisodia, 1992; Thinakaran &
Koo, 2008) (Fig. I-1B and C).
Brain Changes in AD
Tens of billions of neurons transmit chemical and electrical signals
between different brain regions and from the brain to other parts of the body in a
healthy individual. Unlike most cells in human body, neurons continuously repair
themselves and remodel their synaptic connections with other neurons.
Neurogenesis, as well as remodeling, play a pivotal role in learning and memory.
Brain shrinkage resulting from AD is due to neuronal loss, particularly, in brain
regions involved in memory, language, and social behavior, including the
entorhinal cortex and hippocampus as well as the cerebral cortex, respectively.
Three important brain changes associated with AD include Aβ aggregation,
NFTs, and brain chronic inflammation (Association, 2019; Health, 2018).
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Cytotoxic deposition of Aβ plaques, which results from APP processing, is
hypothesized to extracellularly interfere with neuronal communication leading to
cell death (Association, 2019; Glenner & Wong, 1984b; Health, 2018). In healthy
neurons, microtubules are stabilized by tau proteins and involved in transporting
cargo along the cell. Hyperphosphorylation of tau in AD is hypothesized to cause
disintegration of microtubule subunits due to decreased binding affinity of tau
proteins to microtubules. Hyperphosphorylation of tau is mainly hypothesized to
occur by the actions of glycogen synthase kinase 3β (GSK-3β), cyclin-dependent
protein kinase 5 (cdk5), and cAMP-dependent protein kinase (PKA). Intracellular
NFTs, resulting from accumulation of hyper and abnormal phosphorylation of
microtubule-associated tau protein, presumably disrupts soma to dendrite and
axons internal communication and the neuronal transport system (Association,
2019; Brunden, Trojanowski, & Lee, 2009; Health, 2018; Liu et al., 2006; Terry,
1963).
Microglia are brain resident macrophages which comprise the first line of
cellular defense against brain injuries, pathogen invasions, and host-derived
ligands, including pathogen-associated molecular patterns (PAMPs) and dangerassociated-associated molecular patterns (DAMPs), recognized by pattern
recognition receptors (PRRs). Removing the damaged cells by microglia restores
the normal brain environment or cerebral homeostasis. Microglia undergo
morphological changes from ramified cells to an activated amoeboid phenotype
during phagocytosis. It has been well established that APP and Aβ activate
microglia by triggering phagocytosis though PRRs and secretion of
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proinflammatory mediators (i.e. IL-1β, IL-6, and TNF-α). Short-term secretion of
proinflammatory cytokines promotes Aβ uptake by activated microglia. As the
microglia age, they demonstrate phenotype changes and compromised activation
toward stimulations, including Aβ, which may lead to neuronal damage and the
increased risk of AD. In other words, the production of microglial inflammatory
markers is chronically upregulated in AD due to long-term Aβ exposure and
DAMPs accumulation. This leads to compromised microglial Aβ clearance activity
(Fetler & Amigorena, 2005; Kigerl, de Rivero Vaccari, Dietrich, Popovich, &
Keane, 2014; Kreutzberg, 1996; Nimmerjahn, Kirchhoff, & Helmchen, 2005;
Ransohoff & Perry, 2009; Sarlus & Heneka, 2017; Streit, Miller, Lopes, & Njie,
2008) (Fig. I-2).
TREM2 is a cell surface receptor expressed on myeloid cells and is
required for microglial phagocytosis of different substances, including Aβ. The
combination of Aβ with TREAM2 ligands (LDL, APOE, and CLU lipoproteins)
facilitates their uptake by microglia. The presence of mutations in TREM2 or the
deleterious APOE4 isoform, primarily secreted by astrocytes, impairs the
microglia phagocytic activity and advances the risk of AD. Among the ε2, ε3, and

ε4 APOE alleles, which only differ in one amino acid, the APOEε4 isoform
drastically increases the risk of LOAD (Castellano et al., 2011; D. V. Hansen,
Hanson, & Sheng, 2018; Wolfe, Fitz, Nam, Lefterov, & Koldamova, 2018).
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Figure I- 2.

(1) Aβ is extracellularly secreted via the APP amyloidogenic
processing pathway from neurons. (2) A can self-aggregate to
form extracellular plaque deposition. (3) Aβ is intracellularly
cleared via either the phagocytosis-associated combination of
APOE (predominantly secreted by astrocytes) and TREM2
(microglial cell surface receptor) by microglia/macrophages or (4)
APOE and LRP1-mediated endocytosis and lysosomal
degradation through microglia, astrocytes, neurons, etc. (5)
Clearance of Aβ also occurs through both extracellular
proteolytic enzymes, including NEP, IDE, and MMP, and (6)
LRP1-associated efflux across the BBB to the periphery. (7)
Inversely, RAGE receptor influx of Aβ into the brain occurs
across the BBB. (8) Extracellular Aβ along with intracellular
neurofibrillary tangles, resulting from accumulation of
hyperphosphorylated-tau, lead to neuronal death and synaptic
loss. BBB, blood-brain barrier; NEP, neprilysin; IDE, insulin
degrading enzyme; MMP, matrix metalloproteinase. Created with
Biorender.com.
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The neurovascular unit in the central nervous system (CNS) consists of
endothelial cells, pericytes, multiple layers of smooth muscle cells, basement
membrane/basal lamina, astrocytes, neurons, and perivascular microglial cells.
Vascular cells and astrocyte endfeet comprise the blood-brain barrier (BBB).
Astrocytes control homeostasis of the CNS via modulating glutamatergic
neurotransmission, oxidative stress regulation, growth factor secretion, regulating
the extracellular neurotransmitters and ion concentrations, energy storage, and
tissue repair following traumatic injuries. LDLR-related proteins (APOE and APP
receptors), i.e. LRP1 and VLDLR, and advanced glycation end products (RAGE)
receptors are two types of receptors which are involved in Aβ efflux into the blood
circulation and Aβ influx into the brain across the BBB, respectively. A decrease
in LRP1 and an increase in RAGE expression levels in AD can lead to BBB
dysfunction and failure of Aβ clearance. Astrocytes secret APOE, apolipoprotein
J (APOJ) or clusterin, α1-antichymotrypsin (ACT), and α2 macroglobulin (α2-M)
extracellular chaperones which mediate Aβ clearance by facilitating its uptake via
receptor-mediated endocytosis and transportation across the BBB. Compared to
APOE4, APOE3 more effectively clears Aβ due to its higher affinity toward this
protein. Beside astrocytes, other brain parenchyma cells including microglia, and
neurons, endothelial cells, and smooth muscle cells are all involved in
LRP1/LDLR receptor-mediated Aβ clearance. Reactive astrocytes also express
endoproteases for cleavage and degradation of monomeric, oligomeric, and
fibrillar forms of Aβ. These proteolytic enzymes include metalloendopeptidases
neprilysin (NEP), insulin degrading enzyme (IDE), endothelin-converting
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enzymes-1 and -2 (ECE1 and ECE2) as well as matrix metalloproteinase-2 and 9 (MMP-2 and MMP-9). Extensive proliferation of reactive astrocytes in AD
results in an abnormal regulation of ionic concentrations, neurotransmitter
transportations, energy metabolism and Aβ clearance (Beach, Walker, &
McGeer, 1989; Bu, 2009; Z. Cai et al., 2018; Carter et al., 2019; Deane, Bell,
Sagare, & Zlokovic, 2009; Itagaki, McGeer, Akiyama, Zhu, & Selkoe, 1989b; Ries
& Sastre, 2016).
Topographical Distribution of Aβ and Neurofibrillary Tangles
The progressive Aβ deposition in different regions of the brain is classified
into five phases. Phase 1 includes the deposition of Aβ plaques in the frontal,
parietal, temporal, or occipital neocortex. Phase 2 is characterized by spreading
plaque deposition into the allocortical regions, including the entorhinal region,
CA1, and insular cortex. Diencephalic nuclei, caudate nucleus, putamen,
substantia innominata, and the magnocellular cholinergic nuclei of the basal
forebrain comprise the subcortical regions which are affected in phase 3.
Additional β-amyloidosis occurs in specific brainstem nuclei, including inferior
olivary nucleus, the reticular formation of the medulla oblongata, and the
substantia nigra, in phase 4. Phase 5 is characterized by Aβ deposition in
cerebellum and additional brainstem nuclei (Thal, Rub, Orantes, & Braak, 2002).
In contrast, NFTs distribute into brain regions via six stages. Stage I is
characterized by mild alterations in the transentorhinal region. Stage II is more
aggressive and demonstrates tangles in the transentorhinal Pre-α and entorhinal
Pre-α along with mild involvement of the hippocampus CA1 region. The
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entorhinal and transentorhinal layer Pre-α are severely involved in stages III-IV.
Stages III-IV are also called limbic III-IV stages due to aggregation of NFTs in
limbic structures such as the subiculum of the hippocampal formation (stage III)
and amygdala, thalamus as well as claustrum (stage IV). Finally, the
neurofibrillary degeneration occurs in all isocortical areas in stages V-VI (Braak &
Braak, 1991).
Trophic Factors and AD
Nerve growth factor (NGF), a neurotrophic factor, was discovered by Rita
Levi-Montalcini in 1950 for its potential role to promote survival and development
of sympathetic and sensory neurons in the peripheral nervous system. In the
CNS, NGF regulates cholinergic neuronal survival, plasticity, and function (Hefti,
Hartikka, & Knusel, 1989; Levi-Montalcini, 1987). NGF binds to two NGFreceptors (1) the high-affinity tropomyosin-related kinase receptor (TrkANGFR) with
tyrosine kinase activity and (2) the low-affinity transmembrane glycoprotein panneurotrophin receptor (p75NTR) to initiate signal transduction pathways (Huang &
Reichardt, 2003). Due to the loss of cholinergic neurons in the basal forebrain
associated with cognitive deficit and impairment of NGF signaling in AD, NGF is
considered one potential therapeutic intervention (Bartus, Dean, Beer, & Lippa,
1982; K. S. Chen et al., 1997; Hampel et al., 2019; Latina et al., 2017; Mitra,
Behbahani, & Eriksdotter, 2019).
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin
family that was discovered in 1982 (Barde, Edgar, & Thoenen, 1982). BDNF is
synthesized in the cortex, hippocampus, and basal forebrain areas which are
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involved in memory, learning, and cognitive functions. It promotes neurogenesis,
neuronal survival, and function as well as synaptogenesis and synaptic plasticity
via binding to TrkB and p75NTR receptors (Acheson et al., 1995; Huang &
Reichardt, 2003; B. Lu, Nagappan, Guan, Nathan, & Wren, 2013). Reduced
levels of BDNF were reported in patients with mild cognitive impairment, serum
of AD patients, and AD postmortem brains (T. K. S. Ng, Ho, Tam, Kua, & Ho,
2019; Tanila, 2017).
The proangiogenic vascular endothelial growth factor (VEGF) was isolated
and characterized by Napoleone Ferrara in 1989 (Ferrara, 2011). Besides
enhancing angiogenesis and vasculogenesis via binding to tyrosine kinase
receptors of endothelial cells, VEGF contributes to neuroprotection and
neurogenesis (Jin et al., 2002; Millauer et al., 1993; Storkebaum, Lambrechts, &
Carmeliet, 2004). VEGF binds to receptor tyrosine kinases, VEGFR1-R3, with
high affinity (Simons, Gordon, & Claesson-Welsh, 2016). VEGF mediates
angiogenesis, neurogenesis, neuroprotection, and astroglial proliferation in the
neurovascular unit as well as memory improvement via neuronal plasticity and
increasing long-term potentiation in the dentate gyrus (Argandona et al., 2012;
Jin et al., 2002; Licht et al., 2011). VEGF is considered a potential marker to
detect vascular alterations in AD (Mateo et al., 2007; Provias & Jeynes, 2014; J.
B. Zhang et al., 2016).
Insulin growth factor-1 (IGF-1), or somatomedin, was characterized by
Salmon and Daughaday in 1957 due to its ability to stimulate sulfate
incorporation into cartilage (Salmon & Daughaday, 1957). IGF-1 exerts it effect
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through binding to type I IGF-1 receptor (IGF-1R), a type 2 tyrosine kinase
receptor. IGF-1 and IGF-1R have 40% and 60% amino acid sequence homology
to proinsulin and insulin receptor (Samani, Yakar, LeRoith, & Brodt, 2007).
Secretion of GH-releasing hormone (GHRH) from the hypothalamus stimulates
expression of GH by the pituitary gland. This results in the subsequent secretion
of IGF-1 by the liver. Although many tissues produce IGF-1, which functions
through both autocrine/paracrine pathways, the liver is the main source of
circulating IGF-1 (Baxter, 1986; V. S. Lim, 2010; Moller & Becker, 1992). A
deficiency in GH-IGF-1 axis which leads to reduction of GH and IGF-1 signaling
extends lifespan in animal models (Flurkey, Papaconstantinou, Miller, & Harrison,
2001; L. Kappeler et al., 2008; Sun et al., 2013).
Brain-Gut-Microbiota Axis in AD
In the 19th and early 20th century, association of the brain with the gut was
critically investigated by William Beaumont, Ivan Petrovich Pavlov, Walter
Bradford Cannon, Stewart Wolf (Aziz & Thompson, 1998). Later, the pivotal role
of gut flora in modulating the gut-brain axis was recognized (Rhee, Pothoulakis,
& Mayer, 2009). The central nervous system (CNS), including the brain and
spinal cord, bi-directionally communicates with the gastrointestinal (GI) tract, its
enteric nervous system (ENS), and the gut microbiota via the sympathetic and
parasympathetic (vagus nerve) fibers, the hypothalamic-pituitary-adrenal (HPA)
axis, endocrine (gut hormones) signaling, the immune system, metabolic
(tryptophan) signaling, and microbial metabolites (short-chain fatty acids). This
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well-established connection is called the brain-gut-microbiota axis (Dinan &
Cryan, 2017; J. B. Furness, Callaghan, Rivera, & Cho, 2014) (Fig. I-3).
In 1899, the ENS was discovered by W.M. Bayliss and E.H. Starling via
defining “the law of the intestine”, in which intestinal neural circuitry intrinsically
generates gut motility. This is now known as the peristaltic reflex (Bayliss &
Starling, 1899; M. B. Hansen, 2003). Later, it was reported that the ENS is
developed by migration of cells from vagal neural crest to the mammalian bowel
and colonization in the gut during embryogenesis (Gershon, Chalazonitis, &
Rothman, 1993). The human ENS contains 200-600 million neurons which
spread out along the GI tract via two major ganglionic and intervening nerve
plexuses, including the myenteric and submucosal plexuses (J. B. Furness et al.,
2014). The myenteric (Auerbach’s) plexus is located between the longitudinal
and circular smooth muscle layers in the muscularis externa. It contains the
majority of ENS neurons and extends along the digestive tract, inward towards
the mucosa or outward towards the serosa, to regulate bowel relaxation and
contraction. The submucosal (Meissner’s) plexus is situated within the
connective tissue of the submucosa layer. It is adjacent to the intestinal lumen
and distributed from the stomach through the rectum and controls epithelial
secretion and local blood flow (John Barton Furness, 2006; Jabbur, el-Kak, &
Nassar, 1988; Schneider, Wright, & Heuckeroth, 2019). Furthermore, the ENS,
via releasing neurotransmitters, regulates the gut immune system. The epithelial
cells, which line the mucosal surfaces, absorb nutrients and provide a barrier
between the mucosal immune system and luminal contents, such as digestive
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Figure I- 3.

The bidirectional microbiota-gut-brain axis. Intestinal bacteria
communicate with the brain via (1) endocrine (eg. cortisol) and
metabolic, (2) immune (eg. cytokines), and (3) neural (vagus,
sympathetic, and enteric nervous system) pathways. Cortisol
secretion from the HPA axis via systemic circulation regulates
the immune system, gut permeability and barrier function as well
as gut microbial composition. The secreted neurotransmitters
from the sympathetic nervous system modulate intestinal
physiology as well as microbial composition. Conversely, gut
microbiota send signals to the brain and influence behavior via
releasing bacterial metabolites (eg. 5-HT precursors and
SCFAs), induction of cytokine secretion from immune cells,
neurotransmitter secretion from enteroendocrine cells (eg. 5-HT),
and vagal (parasympathetic) afferent nerves. HPA,
hypothalamus-pitutary-adrenal axis; CRF, corticotropin-releasing
factor; ACTH, adrenocorticotropic hormone; 5-HT, 5hydroxytryptamine; SCFAs, short-chain fatty acids; DC, dendritic
cell; MQ, macrophage. Created with Biorender.com.
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enzymes, toxins, and gut microbiota (Collins, Surette, & Bercik, 2012; Turner,
2009).
The ENS interacts with sympathetic and parasympathetic nervous
systems, comprising the autonomic nervous system, which are a part of the
peripheral nervous system. Unlike sympathetic and parasympathetic neurons,
the ENS receives almost no afferent (sensory input) and efferent (motor output)
fibers from the CNS and can independently control gastrointestinal behavior
(Waxenbaum & Varacallo, 2019). Due to the fact that the number of enteric
neurons outnumbers the total sympathetic and parasympathetic neurons and its
phenotypic diversity, neurotransmitters, and signaling molecules are similar to
the CNS, the ENS has been called a “second brain” or “the brain within the gut”
(J. B. Furness et al., 2014; Gershon, 1999; Goldstein, Hofstra, & Burns, 2013).
The sympathetic nervous system, via releasing the neurotransmitters from
adrenergic neurons, such as norepinephrine, decreases intestinal motor function
and secretion as well as changes the gut microbial composition. The vagus
nerve, the major element of the parasympathetic nervous system and consisting
of 80-90% afferent and 10-20% efferent fibers, is responsible for transferring
information between the gut, the largest surface area exposed to the outside
world, and the brain. (Breit, Kupferberg, Rogler, & Hasler, 2018; Collins et al.,
2012; Tubbs et al., 2015).
The hypothalamic-pituitary-adrenal (HPA) axis, enteroendocrine system,
and mucosal immune system comprise the humoral aspect of the brain-gutmicrobiota axis. Enteroendocrine cells secrete cholecystokinin, ghrelin, and 521

hydroxytryptamine (5-HT) to mediate this bi-directional communication. In
response to stress, corticotropin-releasinng factor (CRF) is secreted from the
paraventricular nucleus (PVN) located in hypothalamus and causes the secretion
of adrenocorticotropic hormone (ACTH) from the pituitary gland into the systemic
circulation. This leads to the release of glucocorticoids (cortisol), epinephrine,
and norepinephrine from the adrenal gland cortex. The HPA axis, the major
neuroendocrine system, interacts with the gut microbiota, which includes 100
trillion cells and encodes more than 3.3 million non-redundant genes, over 100fold more genes than the human host genome (Collins et al., 2012; Farzi,
Fröhlich, & Holzer, 2018; Qin et al., 2010).
The Gram-positive Firmicutes (∼51%) and Gram-negative Bacteroidetes
(∼48%) along with Cyanobacteria, Fusobacteria, Proteobacteria, Spirochetes,
Verrucomicrobia as well as different species of fungi, protozoa, and viruses
(∼1%) comprise the GI tract microbiota (Hill et al., 2014). Bacterial metabolites as
well as secreted cytokines and hormones from mucosal immune cells and
enteroendocrine cells in response to gut microbiota, respectively, can reach the
brain via the bloodstream and area postrema or vagus nerve (Collins et al.,
2012).
Considering the fact that the brain bi-directionally communicates with the
gut, CNS disorders may be affected by a dysfunctional GI tract and
pathophysiologically, one may precede the other (Kujawska & Jodynis-Liebert,
2018). For instance, autism spectrum disorder (ASD) is a neurodevelopmental
disease which manifests early in life via deficits in social interaction and
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communication as well as repetitive behaviors. Meta-analysis studies report
dramatic prevalence of GI dysfunction in ASD children compared to healthy
controls (McElhanon, McCracken, Karpen, & Sharp, 2014).
Parkinson’s disease (PD), a neurodegenerative disorder, is diagnosed by
non-motor (olfactory disturbances, sleep disorders, depression, and constipation)
symptoms and motor (bradykinesia, rigidity, tremor, and postural instability)
manifestations correlating with intracellular α-synuclein aggregation and loss of
dopaminergic neurons. Precedence of constipation before development of motor
symptoms and also accumulation of α-synuclein in the ENS as well as dorsal
motor nucleus of the vagus nerve, support the idea that PD pathological
hallmarks may originate in the ENS by mucosal invasion of a neurotropic
pathogen that is later transmitted to the CNS (Braak, Rub, Gai, & Del Tredici,
2003; Klingelhoefer & Reichmann, 2015; Kujawska & Jodynis-Liebert, 2018).
APP is expressed in human neuronal (ENS) and non-neuronal tissues
(endothelial cells) of the GI tract (Cabal et al., 1995). In addition, Aβ has been
detected in non-neural tissues of some aged healthy individuals and in nonneural tissues, including intestine and blood vessels, of AD patients as well as in
the ENS of APP overexpressing transgenic mice, suggesting that AD may be a
systemic disorder (Joachim, Mori, & Selkoe, 1989; Semar et al., 2013). Elevated
levels of APP and Aβ in the ENS and intestinal epithelial cells correlates with
increased levels of luminal IgA, phenotype changes of immune cells, and
proinflammatory markers in the AβPP/PS1 mouse model of AD. These results
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are consistent with findings in the intestines of AD patients (K. L. Puig et al.,
2015).
Inflammatory Bowel Disease (IBD)- Colitis
Inflammatory bowel disease (IBD), including Crohn’s disease and
ulcerative colitis, is a chronic relapsing inflammatory disease with increasing
incidence and prevalence. IBD develops in young adulthood and continues
throughout life. Aged individuals with IBD consist of patients with elderly-onset
occurring at age ≥ 60 years and older patients who were diagnosed at younger
ages (Cosnes, Gower-Rousseau, Seksik, & Cortot, 2011; Taleban, Colombel,
Mohler, & Fain, 2015). It is clinically characterized by diarrhea+/- blood,
abdominal pain, weight loss, and fatigue (Neurath, 2014). Anxiety, depression,
and cognitive and memory dysfunctions are also characterized in IBD patients
(Attree, Dancey, Keeling, & Wilson, 2003; Kurina, Goldacre, Yeates, & Gill, 2001;
Petruo, Zeißig, Schmelz, Hampe, & Beste, 2017). Epithelial monolayer lining in
the GI tract is a dynamic barrier which is maintained intact by the balance
between epithelial apoptosis and proliferation (Chassaing, Aitken, Malleshappa,
& Vijay-Kumar, 2014a). Genetic, environmental factors, and irregular immune
response to gut microbiota may cause epithelial barrier dysfunction in the
intestinal mucosa, although the genetic contribution to elderly-onset IBD is less
than young-onset disease (Ananthakrishnan et al., 2016; Taleban et al., 2015).
Subsequent to bowel epithelial damage, commensal bacteria and microbial
metabolites are translocated into the bowel wall, where intestinal immune cells,
such as dendritic cells and macrophages, are activated via toll-like receptor
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(TLR) signaling and secrete large amount of pro-inflammatory cytokines,
including IL-1β, IL-6, IL-18, and TNF-α. The imbalance between extreme and
deficient apoptosis and/or anti-inflammatory and pro-inflammatory immune
responses develops into GI tract diseases including chronic intestinal
inflammation (Chassaing et al., 2014a; Neurath, 2014; S. C. Ng et al., 2011).
Initiation of inflammation in the gut may induce CNS changes which lead to
altered brain functions. For example, TNF-α is the main pro-inflammatory
cytokine in IBD pathology and is targeted for treatment of the disease (Ślebioda
& Kmieć, 2014). Increased serum levels of TNF-α due to systemic inflammation
exacerbates cognitive impairment and neurodegeneration through activation of
primed microglia in AD subjects (Holmes et al., 2009). Additionally, the brain may
contribute to IBD severity and pathogenesis. Chronic stress, stressful life events,
and depression exacerbate IBD, likely, via the autonomic nervous system and
the HPA axis, the two stress pathways (Bernstein et al., 2010; Mawdsley &
Rampton, 2005; Sgambato, Miranda, Ranaldo, Federico, & Romano, 2017).
Colitis-Associated Colorectal Cancer (CAC)
Colorectal cancer (CRC) is the third most common cancer-associated
cause of death in the United States, according to the CDC. In most cases, a
somatic mutation in Wnt signaling pathway genes results in sporadic CRC. It is
occasionally caused by hereditary mutations, such as familial adenomatous
polyposis (FAP) and hereditary non-polyposis CRC (HNPCC ) caused by Lynch
syndrome (Groden et al., 1991; Mármol, Sánchez-de-Diego, Pradilla Dieste,
Cerrada, & Rodriguez Yoldi, 2017; Rowan et al., 2000). Prolonged non-resolving
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ulcerative colitis, which was first reported in the 1920s, also contributes to CRC
development but to a lesser extent (BARGEN, 1928; Breynaert, Vermeire,
Rutgeerts, & Van Assche, 2008; Jess, Frisch, & Simonsen, 2013). Proinflammatory cytokines, including IFN-γ and TNF-α, exacerbate colonic barrier
loss and ulcers via tight junction dysregulation and promoting intestinal epithelial
cell apoptosis (Nava et al., 2010; Su et al., 2013). Whereas, intestinal activation
of IL-22-STAT3 leads to mucosal wound healing. Additionally, IL-6 through the
NF-κB-IL-6-STAT3 cascade prevents apoptosis of normal and pre-malignant
intestinal epithelial cells (IECs) and promotes tumorigenesis of tumor initiating
IECs (Greten et al., 2004; Grivennikov et al., 2009; Pickert et al., 2009). These
results suggest that cytokine imbalance plays a pivotal role in dysregulation of
IEC proliferation contributing to colitis-associated colorectal cancer (CAC).
In CAC, early mutations in the tumor suppressor p53 gene in IECs and the
presence of TNF-α and PAMPs lead to NF-κB upregulation. Subsequently, NFκB activation can induce IL-6 secretion involved in tumorigenesis as well as ROS
activation which causes DNA damage followed by loss of the APC gene as a late
event in this type of CRC (Bollrath & Greten, 2009; Cooks et al., 2013;
Grivennikov et al., 2009; Kameyama et al., 2018; Tilstra et al., 2012). Barrier
disruption as a result of colonic dysplasia causes bacterial invasion into the
lamina propria and exacerbates the tumor pro-inflammatory milieu (Brennan &
Garrett, 2016).
An inverse relationship between AD and cancer risk is reported in different
human and animal studies (Ham et al., 2018; Ibáñez, Boullosa, Tabarés26

Seisdedos, Baudot, & Valencia, 2014; J. E. Lee, Kim, & Lee, 2018; Musicco et
al., 2013; Sherzai, Parasram, Haider, & Sherzai, 2020). However, an
epidemiological investigation revealed that high constipation prevalence is
common in both AD and CRC (T. Zhang et al., 2018).
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CHAPTER II
IGF-1R INHIBITOR AMELIORATED NEUROINFLAMMATION
IN AN ALZHEIMER’S DISEASE TRANSGENIC MOUSE MODEL
Introduction
Alzheimer’s disease (AD), as the most common form of dementia,
comprises 60%-80% of all cases ("2016 Alzheimer's disease facts and figures,"
2016). Extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary
tangles are AD pathological features hypothesized to lead to neuronal death and
cognitive dysfunction (Glenner & Wong, 1984b; Terry, 1963). Since aging is the
main risk factor for AD, slowing down this process may delay disease onset or
progression (Guerreiro & Bras, 2015). The growth hormone (GH)/insulin-like
growth factor (IGF-1) signaling pathway is hypothesized to be one of the primary
pathways regulating lifespan in general. Partial inactivation of the IGF-1 receptor
(IGF-1R) gene or insulin-like signaling extends longevity and postpones agerelated dysfunction in nematodes, flies, and rodents (Holzenberger et al., 2003;
Laurent Kappeler et al., 2008; Kenyon, 2010; Taguchi, Wartschow, & White,
2007; Tatar, Bartke, & Antebi, 2003; Xu et al., 2014). Also, genetic mutations in
the human IGF-1R, GH-R or low levels of IGF-1 correlate with lifespan extension
(Guevara-Aguirre et al., 2011; Milman et al., 2014; Suh et al., 2008; van der
Spoel et al., 2015). Therefore, pharmacologic inhibition of the GH/IGF-1 pathway

28

is a promising strategy for impeding or slowing down age-related diseases
(Longo et al., 2015).
However, the role of IGF-1 in regulating age-associated AD remains
unclear. For instance, lower serum IGF-1 levels correlate with increased
cognitive decline and risk of AD (Okereke et al., 2007; Westwood et al., 2014). In
addition, patients with familial AD demonstrate lower levels of circulating IGF-1
compared to controls (Mustafa et al., 1999). An ex vivo study revealed IGF-1
resistance along with insulin resistance through the PI3K pathway in AD patient
brains (Talbot et al., 2012). Finally, IGF-1 treatment diminished Aβ accumulation
by improving its transportation out of the brains of AD mouse models while
IGF-1R inhibition aggravated both behavioral and pathological AD symptoms in
mice (E. Carro, Trejo, Gomez-Isla, LeRoith, & Torres-Aleman, 2002; Eva Carro
et al., 2006).
On the other hand, administration of a potent inducer of circulating IGF-1
levels (MK-677) failed to delay AD progression in a randomized trial (Sevigny et
al., 2008). Also, acute or chronic delivery of IGF-1 exerted no beneficial effect on
AD pathological hallmarks in rodent models in vivo (Lanz et al., 2008). Moreover,
high levels of serum IGF-1 were detected in individuals diagnosed with AD or
other forms of dementias in one cross-sectional study (Johansson et al., 2013).
Decreased insulin/IGF-1 signaling (IIS) in aged women carrying polymorphisms
which lead to reduced IIS activity correlated with better cognitive behavior in
another study (Euser, van Heemst, van Vliet, Breteler, & Westendorp, 2008). In a
familial study, higher serum IGF-1 at midlife increased the risk of late-onset AD
29

(van Exel et al., 2014). Middle-aged and older males with high circulating IGF-1
levels at baseline were diagnosed with cognitive impairment after approximately
8 years in a longitudinal study (Tumati, Burger, Martens, van der Schouw, &
Aleman, 2016). A higher prevalence and incidence of dementia and AD were
associated with higher levels of IGF-1R stimulating activity in an elderly,
population-based cohort study (de Bruijn et al., 2014). Consistent with these
findings, a body of studies have demonstrated that genetically ablating IGF-1R
signaling improves neuroprotection and protects against AD progression by
alleviating AD hallmarks including Aβ deposition, neuroinflammation, neuronal
and synaptic loss, and behavioral dysfunction in AD mouse models (Cohen et al.,
2009; Freude et al., 2009; George et al., 2017; Gontier, George, Chaker,
Holzenberger, & Aïd, 2015).
Presumably, this dichotomy of effects is, in part, mediated through effects
of IGF-1 on its receptor. The IGF-1R and the insulin receptor (IR) are
homologous tyrosine kinase proteins with remarkably different functions (Arcaro,
2013; Larsson, Girnita, & Girnita, 2005; Rothenberg, White, & Kahn, 1990). Upon
binding of IGF-1R ligands (IGF-1, IGF-2, and supraphysiological concentration of
insulin), the receptor becomes auto-phosphorylated on three key tyrosine
residues (Y1131, Y1135, and Y1136) in the activation loop (Baserga, 1999;
Favelyukis, Till, Hubbard, & Miller, 2001; LeRoith, Werner, Beitner-Johnson, &
Roberts, 1995). Phosphorylation of this receptor leads to activation of two major
signaling pathways including RAS/RAF/MEK/ERK and PI3K/Akt which results in
proliferation and protein synthesis/anti-apoptosis/autophagy, respectively
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(Gallagher & LeRoith, 2010; Gontier et al., 2015). Inhibition of IGF-1R-mediated
signaling is considered a viable therapeutic strategy against cancer, including
glioblastoma, to confront tumor growth (Girnita et al., 2004; Yin et al., 2010).
PPP, a cyclolignan compound, is a potent, selective, competitive, and reversible
inhibitor which targets IGF-1R autophosphorylation at the substrate level (Girnita
et al., 2004). Thus, it has no described effect on the function of IR or other
tyrosine kinase receptors (Girnita et al., 2004; R. Vasilcanu et al., 2008).
Inhibition of IGF-1R by PPP preferentially downregulates the PI3K/Akt signaling
pathway through blocking activation loop phosphorylation (D. Vasilcanu et al.,
2004).
Based on the potential role of IGF-1R suppression against AD
development and according to our previous data which reported diminished
gliosis and Aβ burden in the df/df/AβPP/PS1 transgenic mice which express low
levels of brain IGF-1 (Kendra L. Puig et al., 2016), we hypothesized that applying
a short-term pharmaceutical intervention might attenuate disease presentation.
To test this idea, we intraperitoneally injected PPP into the AβPP/PS1 mouse line
and wild type littermate controls for a week to investigate changes in gliosis and
plaque deposition.
Methods
Animals

In this study, the wild-type (WT) C57BL/6J mouse line and the C57BL6
AβPP/PS1 (strain 005864 B6.Cg-Tg (AβPPswe,PSEN1dE9)85Dbo) transgenic
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mice were originally purchased from the Jackson Laboratory (Bar Harbor, Maine)
and maintained, as a colony, under standard housing conditions including a 12 h
light:12 h dark cycle and 22 ± 1 °C temperature with ad libitum access to food
and water at the University of North Dakota Center for Biomedical Research.
This transgenic mouse model of AD expresses the human amyloid beta (A4)
precursor protein (hAβPP) and the human presenilin 1 (hPSEN1), respectively,
carrying the Swedish and deltaE9 mutations under the control of the mouse prion
promoter. AβPP/PS1 mice develop significant amyloid plaque deposition and
gliosis in their brains by 6-7 months of age. Due to limited animal availability, only
male littermate control WT and AβPP/PS1 mice at 9-10 months of age (n = 7-9
per genotype) were used. They were randomly divided into vehicle and drug
treated groups for 7-day treatments. 24 h (day 8) after ending the treatments,
mice were euthanized followed by cardiac perfusion and the blood, brains,
spleens, and livers were collected to quantify histologic and biochemical
changes. All procedures involving animals were reviewed and approved by the
UND Institutional Animal Care and Use Committee (UND IACUC). The
investigation conforms to the National Research Council of the National
Academies Guide for the Care and Use of Laboratory Animals (8th edition).
Microglia Cultures
Microglia were obtained from cortices of postnatal 0-3-day-old C57BL/6J
pups. Cortices were briefly trypsinized, triturated, and cultured for 10-14 days on
top of an adherent astrocyte layer from the same cortices in a T-75 flask.
Complete media consisting of DMEM/F12 with 10% FBS, 5% horse serum
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penicillin and streptomycin was partially replaced at 7 days in vitro. Because the
microglia are loosely adhered and floating, to isolate microglia from the
astrocytes, flasks were shaken to remove any loosely adhered microglia but not
astrocytes. Media was collected and centrifuged briefly to pellet microglia.
Microglia were resuspended into complete media, counted and plated onto polyL-lysine coated 96 well plates at a density of 40,000 cells/well. Cells were
pretreated with or without 100ng/mL IGF-1 (R&D Systems, Minneapolis, MN) for
7 days prior to Aβ stimulation. Fresh complete media with or without IGF-1 was
replaced every two days.
Antibodies and Reagents
The Y188 antibody targeting AβPP was purchased from Abcam
(Cambridge, MA, USA). The 4G10 antibody to target p-tyrosine (05-321) was
purchased from Millipore (Darmstadt, Germany). The anti-oligomer antibody,
A11, and anti-fibrillar protein antibody, OC, were gifts from Rakez Kayed. Anti-Aβ
6E10 antibody was purchased from Covance (Emeryville, CA, USA). Iba-1 and
CD68 (MCA1957) antibodies against microglia markers were purchased from
Wako Chemicals USA, Inc (Richmond, VA, USA) and BIO-RAD (CA, USA),
respectively. Antibodies targeting α-tubulin (TU-02: sc-8035), actin (I-19: sc1616), and GAPDH (6C5: sc-32233) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies against GFAP (D1F4Q) to
target astrocytes, p-AKT (Ser473) (193H12), AKT (pan) (C67E7), p-p44/42
MAPK (p-ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2), IGF-1R β, pSAPK/JNK (Thr183/Tyr185), and SAPK/JNK were purchased from Cell Signaling
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Technology, Inc (Danvers, MA, USA). To detect p-IGF-1R (pY1161) for brain
immunohistochemistry and p-IR/IGF1-R (pYpY1162/1163) for western blotting,
antibodies were purchased from Abcam (Cambridge, MA, USA) and Life
Technologies (Grand Island, NY, USA), respectively. The 4G8 antibody against
the Aβ peptide was purchased from Biolegend (San Diego, CA, USA). The
mouse on mouse (M.O.M) kit, Vector VIP kit, biotinylated anti-rat, anti-rabbit, and
anti-mouse antibodies were purchased from Vector Laboratories Inc
(Burlingame, CA, USA). The horseradish peroxidase conjugated secondary
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Picropodophyllin (PPP), IGF-1R inhibitor, was purchased from
EMD Millipore (Billerica, MA, USA). The cytokine ELISA kits were purchased
from R&D Systems (Minneapolis, MN, USA). The human Aβ1-40/42 ELISA kits
were purchased from EMD Millipore (Billerica, MA, USA).
Intraperitoneal Injection of PPP
The male AβPP/PS1 and age-matched WT mice were randomly divided
into two treatment (drug and vehicle) groups per genotype. PPP dissolved in
DMSO was given to drug treated groups with a dosage of 1mg/kg/day while the
vehicle groups received DMSO via ip. injection, totaling 7 days. Efficacy of this
PPP concentration (1mg/kg) was confirmed in our preliminary studies.
Tissue Enzyme-Linked Immunosorbent Assays (ELISA)
On the collection day, spleen and right temporal cortices of brain
hemispheres were isolated and flash frozen. Temporal cortices and spleens were
lysed in Raybiotech lysis buffer and centrifuged (17968 g, 4°C, 10 min) and
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cytokine and soluble Aβ1-40/42 ELISAs were performed from the supernatants
according to the manufacturer’s protocol. The temporal cortices pellets were
resuspended in 5M guanidine HCL/50mM Tris HCL, pH 8.0, centrifuged
(17968 g, 4°C, 10 min), and the supernatants were removed to quantify insoluble
Aβ1-40/42 levels by ELISA according to the manufacturer’s protocol. The Bradford
method or BCA kit (Thermo Scientific, IL, USA) were used to quantify protein
concentrations (Bradford, 1976).
Immunohistochemistry (IHC)
The left-brain hemisphere was immersion fixed in 4% paraformaldehyde,
replaced with 30% w/v sucrose in PBS three times. Briefly, the brains were then
embedded in 15% gelatin followed by immersion fixing in 4% paraformaldehyde,
15%, then 30% sucrose. The gelation blocks were serially sectioned (40µm) via
freezing microtome (Kumi Nagamoto-Combs, Gunjan D. Manocha, Kendra Puig,
& Colin K. Combs, 2016). The serial sectioned brains were immunostained using
anti-Aβ (4G8; 1:1000 dilution), Iba-1 (1:1000 dilution), GFAP (1:1000 dilution),
and CD68 (1:1000 dilution) antibodies following citrate antigen retrieval, and pIGF-1R (1:1000 dilution), and p-tyrosine (4G10; 1:1000 dilution) antibodies
followed by their respective secondary antibodies. Vector VIP was used to
visualize the immunoreactivity and images were taken using an upright Leica
DM1000 microscope and Leica DF320 digital camera system.
Immunohistochemistry quantitation of hippocampi was performed via calculating
the mean optical density (n=6). Adobe Photoshop software (Adobe Systems, San
Jose, CA) was used to make figures.
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Western Blotting
Flash frozen hippocampi and livers were lysed in RIPA buffer (20 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 1 mM EDTA, 1 mM EGTA,
0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1% SDS, and 0.5%
deoxycholate) with protease inhibitors (AEBSF 1mM, Aprotinin 0.8 M, Leupeptin
21 M, Bestatin 36 M, Pepstatin A 15 M, E-64 14 M), centrifuged (14,000 rpm,
4°C, 10 min), and the supernatants were collected. Hippocampal proteins were
resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene difluoride membranes (PVDF) for
western blotting using anti- p-IR/IGF1-R, IGF-1Rβ, p-AKT, AKT, p-JNK, JNK, pERK, ERK, p-tyrosine, AβPP (Y188), CD68, GFAP, and α-tubulin (loading
control) antibodies. For the liver western blotting, anti- p-IR/IGF1-R, IGF-1Rβ,
and actin (loading control) antibodies were used. The BCA kit (Thermo Scientific,
IL, USA) was used to quantify protein concentrations. Enhanced
chemiluminescence was used to detect antibody binding using an Aplegen
Omega Lum G imaging system. Optical density values were normalized to their
respective loading controls (p-IGF-1R, p-AKT, p-JNK, and p-ERK blots against
their respective IGF-1R, AKT, JNK, and ERK total proteins and p-tyrosine, AβPP,
CD68, and GFAP blots against α-tublin) from the same membrane, and then
averaged (± SEM).
Dot Blot
Total, oligomeric, and fibrillar protein from the hippocampal lysates in
RIPA buffer were dot blotted onto PVDF membranes and detected using 6E10,
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A11, and OC antibodies, respectively. Enhanced chemiluminescence was used
to detect antibody binding using an Aplegen Omega Lum G imaging system.
Optical density values were normalized to α-tubulin, loading control.
MTT Assay
Microglia were pretreated with or without 100ng/mL IGF-1 for 7 days in
complete medium on a clear 96 well plate prior to Aβ stimulation. Media was
replaced with serum free DMEM/F12 with or without 100ng/mL IGF-1 or 100nM
Aβ42 (A-1165, rPeptide, Athens, GA) for 24 h. Aβ oligomers were resuspended
with water at a 250µM concentration for 5 min and slowly inverted to mix. Aβ
conformation was confirmed via western blots for each experiment. MTT reagent
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added to the
media at a concentration of 100µg/mL for 1 h. Media was removed and replaced
with isopropanol. Optical density was read at 560nm with a 650nm correction
wavelength on a Bio-Tek ELx800 plate reader (Winooski, VT).
Phagocytosis Assay
Microglia were pretreated with or without IGF-1 for 7 days, on a black 96
well plate prior to Aβ stimulation. Media was replaced with DMEM/F12 only with
or without 100ng/mL IGF-1, 1µM FITC-human Aβ, or FITC-Escherichia coli
bioparticle as a positive control, 0.125mg/mL. Phagocytosis was measured by
the uptake of fluorescein isothiocyanate (FITC)-conjugated Aβ42. The Aβ42
peptide was fibrillized as recommended by the manufacturer (rPeptide, Athens
GA) and previously described (Floden, 2006). Cells were treated for 6 h, media
was removed, and wells were rinsed with 0.25mg/mL trypan blue in PBS to
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quench any extracellular peptide or bioparticles that were not internalized. The
intracellular fluorescence was read at 480nm excitation and 520nm emission via
Bio-Tek FLx800 fluorescent plate reader (Winooski, VT).
Culture Media Enzyme-Linked Immunosorbent Assays (ELISA)
Microglia were pretreated with or without IGF-1 for 7 days in complete
media. Media was replaced with serum free DMEM/F12 with or without
100ng/mL IGF-1, or 100nM Aβ42 for 24 h. Aβ oligomers were resuspended with
water at a 250µM concentration for 5 min and slowly inverted to mix. Aβ
conformation was confirmed via western blots for each experiment. Media was
removed and TNF-α levels quantified using a mouse TNF-α DuoSet ELISA kit
according to the manufacturer’s protocol (R&D Systems, Minneapolis, MN). The
optical density was read on a Bio-Tek ELx800 plate reader (Winooski, VT) at
450nm and 550nm corrected wavelength and pg/mL TNF-α was calculated via
standard curve.
Statistical Analysis
The in vivo data were analyzed by two-way ANOVA multiple comparisons
followed by Uncorrected Fisher’s LSD test using GraphPad Prism 8 software.
One-way ANOVA followed by Uncorrected Fisher’s LSD test was used to
analyze the in vitro data including the MTT assays, phagocytosis assays, and
TNF-α ELISAs. Data are represented as the mean ± SEM. Significance is
indicated by P value measurements with a P < 0.05 considered significant;
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Results
Aβ Levels Were Attenuated by IGF-1R Inhibitor Treatment
of AβPP/PS1 Mice
The inhibitory effect of drug on IGF-1R phosphorylation was confirmed via
i.p. injection of 1mg/kg PPP. The wild type and AβPP/PS1 controls as well as the
drug treated AD mouse model were euthanized and the hippocampal tissues
were collected 15 minutes after the injection. Western blot results showed
downregulation of p-IGF-1R and p-tyrosine levels indicative of attenuation of IGF1R signaling (Fig. II-1).
Both WT and AβPP/PS1 lines (9-10-month-old) were treated with
1mg/kg/day PPP in order to determine the impact of IGF-1R inhibition on Aβ
deposition. ELISA analysis indicated a significant decrease of insoluble Aβ1-40/42

Figure II- 1.

i.p. administration of 1mg/kg PPP decreased p-IGF-1R and
p-tyrosine levels in AβPP/PS1 mouse brains. Hippocampi from
vehicle wild type and AβPP/PS1 as well as PPP treated
AβPP/PS1 mice were collected 15 min following ip. injection of
1mg/kg PPP. Western blots were performed to investigate the
protein changes in including IGF-1R, p-IGF-1R, and p-tyrosine.
GAPDH was used as the loading control.
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but not soluble Aβ1-40/42 levels in temporal cortices of AβPP/PS1 mice treated
with PPP compared to vehicle controls (Fig. II-2A). AntiAβ immunohistochemistry quantitation of hippocampi regions revealed no
dramatic Aβ level changes. However, plaque density reduced in the drug treated
AD mice versus the vehicle treated group, represented via higher magnification
(Fig. II-2B). As an additional means of addressing changes in Aβ, we performed
dot blot analysis from hippocampal lysates using anti-oligomer antibody, A11,
anti-fibril antibody, OC, and total Aβ antibody, 6E10. Dot blots showed no change
in A11 detectable protein due to IGF-1R inhibition (Fig. II-2C). Contrary to our
expectations, the dot blot results did not show a decrease in OC
immunodetection as was predicted from the ELISA, perhaps due to a lack of
specificity of OC for Aβ1−40/42 only (Fig. II-2C). These findings suggest that
insoluble Aβ plaque deposition, in particular, was affected by IGF-1R function.
Microgliosis Was Attenuated in PPP Treated AβPP/PS1 Mice
Brain inflammatory changes are hypothesized to be a critical component
of AD pathophysiology mediated, in part, by Aβ-stimulated microglial activation
and expression of inflammatory cytokines in AD brains (S.-H. Choi et al., 2013;
Itagaki, McGeer, Akiyama, Zhu, & Selkoe, 1989a; Marco Prinz, Josef Priller,
Sangram S. Sisodia, & Richard M. Ransohoff, 2011; W.-Y. Wang, M.-S. Tan, JT.
Yu, & L. Tan, 2015). Based on the attenuated plaque deposition and insoluble Aβ
levels in the PPP treated AβPP/PS1 mice, we expected that inactivation of IGF1R signaling via PPP would also alter reactive gliosis. To assess the impact of
PPP treatment on glial activation, immunohistochemistry was performed.
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Microglial activation was visualized using two different antibodies, anti-Iba-1 and
anti-CD68. PPP treatment attenuated the Aβ-associated hippocampi
immunoreactivity for CD68 but not Iba-1 antibody supporting the idea that IGF1R signaling may be contributing to a reactive microglia phenotype (Fig. II-3).
Interestingly, astrocyte activation, assessed using anti-GFAP
immunoreactivity, did not demonstrate any robust changes following PPP
treatment suggesting an uncoupling of astrogliosis following inhibition of IGF-1R
signaling (Fig. II-3). To begin assessing what cell types might be affected by IGF1R inhibition in the brain, antibodies for the phosphorylated, active form of the
IGF-1R (p-IGF-1R) and p-tyrosine were used for immunostaining. AβPP/PS1
mice demonstrated a robust plaque-associated, microglia-like pattern of p-IGF1R and p-tyrosine immunoreactivity suggesting that microglia are the cell types
with the highest levels of active IGF-1R signaling in these mice (Fig. II-4).
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Figure II- 2.

IGF-1R inhibitor treatment attenuated Aβ levels in AβPP/PS1
mice. A) Temporal cortex lysates collected from male wild type
(WT) and AβPP/PS1 mice, treated with vehicle (DMSO) or
picropodophyllin (PPP, 1mg/kg) for 7 days, were used to perform
ELISAs for insoluble and soluble Aβ1-40/42, Data are mean ±
SEM, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001 (n=7-9
animals). B) Immunohistochemistry was performed on both WT
and AβPP/PS1 mouse brains using anti-Aβ (4G8) antibody and
mean optical density was measured (n=6 animals/condition).
Representative hippocampal images are shown. C) Hippocampal
lysates from vehicle and PPP treated WT and AβPP/PS1 mice
were dot blotted to quantify total Aβ (6E10), oligomeric peptide
(A11), and fibrillar peptide (OC) changes. Data are mean O.D. ±
SEM, **p<0.01, ***p<0.001, and ****p<0.0001 (n=5 animals),
(Fisher’s LSD test).
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Figure II- 3.

IGF-1R inhibitor treatment attenuated microgliosis but not
astrocytosis immunoreactivity in AβPP/PS1 mice.
Immunohistochemistry was performed from vehicle (DMSO) and
PPP (1mg/kg, 7 days) treated WT and AβPP/PS1 mouse brains
using anti-Iba1, anti-CD68 (markers of microglia), and anti-GFAP
(astrocyte marker) antibodies and mean optical density was
measured. Antibody binding was visualized using Vector VIP as
the chromogen. Representative hippocampal images are shown
(n=6 animals/condition).
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Figure II- 4.

p-IGF-1R and p-tyrosine immunoreactivity demonstrated a
microglial-like pattern. Immunohistochemisty was performed
from vehicle and PPP treated wild type and AβPP/PS1 mouse
brains using p-IGF-1R and p-tyrosine (4G10) antibodies.
Representative hippocampal images are shown via 20x
magnification.

PPP Decreased Protein Markers of Microglial Activation
To provide a more quantitative assessment of changes in microgliosis and
IGF-1 receptor inhibition following PPP treatment, western blot analysis of
hippocampi was performed. In order to quantify PPP-dependent changes in IGF1R signaling, protein levels of active IGF-1R and p-IGF-1R were quantified. pIGF-1R protein levels were increased in AβPP/PS1 mice compared to wild type
controls and were unaffected by PPP treatment (Fig. II-5). Kinases associated
with the IGF-1R response were also compared in treated versus untreated mice.
Similar to the IGF-1R findings, active p-Akt and p-JNK levels were not altered by
PPP treatment of AβPP/PS1 mice compared to wild type controls (Fig. II-5).
Levels of active, p-ERK did not differ between strain and treatment (Fig. II-5). To
better support the microglial qualitative immunostaining results, protein levels of
CD68 and p-tyrosine were also quantified. Total protein p-tyrosine levels were
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Figure II- 5.

p-tyrosine and CD68 levels were attenuated by inhibitor
treatment in AβPP/PS1 mice. Hippocampal lysates from vehicle
and PPP (1mg/kg, 7 days) treated WT and AβPP/PS1 mice were
A) western blotted to B) quantify protein changes related to IGF1R signaling, microgliosis, and AβPP levels. p-IGF-1R, p-AKT, pJNK, and p-ERK blots were normalized to their respective IGF1R, AKT, JNK, and ERK loading controls. The p-tyrosine, AβPP,
CD68, and GFAP blots were normalized to their respective αtublin loading controls. Data are mean O.D. ± SEM, *p<0.05,
**p<0.01, ***p<0.001, and ****p<0.0001 (n=5 animals), (Fisher’s
LSD test).

assessed based upon our previous studies which indicated a tyrosine kinasedependent activation of microglia in response to Aβ oligomer stimulation
(Dhawan, Floden, & Combs, 2012). PPP treated AβPP/PS1 mice demonstrated a
significant decrease in both CD68 and p-tyrosine protein levels validating a drugdependent decrease in microgliosis (Fig. II-5). In agreement with our ELISA, dot
blot, and immunostaining results, protein levels of AβPP were not significantly
altered by PPP treatment in either wild type or AβPP/PS1 mice (Fig. II-5). As
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expected, based upon the immunostaining results, the AβPP/PS1-associated
increase in GFAP protein levels was not attenuated by PPP treatment (Fig. II-5).
PPP Treatment Did Not Affect Phosphorylation Levels of Liver IGF-1R
Although the PPP-mediated inhibitory effect on microgliosis did not
correlate with a long-term reduction in brain levels of p-IGF-1R, we investigated
whether the drug was exerting any maintained effect on peripheral p-IGF-1R
levels. Based upon the high expression of IGF-1 and its receptor in the liver, we
quantified liver phosphorylation levels of the receptor (Mauras, 1997). Unlike the
brain, livers of AβPP/PS1 mice demonstrated no elevation in levels of p-IGF-1R
compared to wild type mice demonstrating that the elevated activity associated
with disease differs across organs and is unique to the brain (Fig. II-6). However,
like the brain, PPP treated wild type and AβPP/PS1 mice demonstrated no
significant decrease in p-IGF-1R protein levels compared to the vehicle treated
groups demonstrating that the drug regimen had no lasting adverse effects on
IGF-1R signaling (Fig. II-6).

46

Figure II- 6.

Liver p-IGF-1R levels were not altered by inhibitor treatment in
AβPP/PS1 mice. Liver lysates from vehicle and PPP (1mg/kg, 7
days) treated WT and AβPP/PS1 mice were A) western blotted
to B) quantify p-IGF-1R protein changes. p-IGF-1R blots were
normalized to their respective IGF-1R loading controls. Actin was
used as a loading control. Data are mean O.D. ± SEM, **p<0.01
(n=5 animals), (Fisher’s LSD test).

PPP Treated AβPP/PS1 Mice Had Reduced Levels of
Multiple Cytokines in the Temporal Cortex
Cytokine levels were quantified from the temporal cortices of vehicle and
PPP treated mice to correlate with the observed changes in microglial activation.
Vehicle treated AβPP/PS1 mice had significantly higher levels of GM-CSF, IL1β, and IL-6 compared to vehicle treated wild type mice validating an immune
phenotype in the brains of AD mice (Fig. II-7).
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Figure II- 7.

IGF-1R inhibitor treatment attenuated the levels of select
cytokines in the brains of AβPP/PS1 mice. ELISAs were
performed to quantify levels of cytokines in temporal cortex
lysates from WT and AβPP/PS1 mice that were vehicle or PPP
(1mg/kg, 7 days) treated. Data are mean values normalized to
tissue wet weight ± SEM, *p<0.05 (n=6-8 animals), (Fisher’s LSD
test).
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More importantly, PPP treatment significantly decreased eotaxin, TNF-α,
IL-1α, IL-1β, and IL-10 levels in the drug treated AβPP/PS1 mice compared to
their vehicle controls (Fig. II-7). The levels of other protein markers did not
change due to different strains or drug treatment (Fig. II-8). These data
corresponded well with the observed reduction in microglial reactive phenotype
and suggested that inhibition of IGF-1 signaling is sufficient to attenuate select
proinflammatory cytokines levels in brains of AD mice.

Figure II- 8.

PPP did not affect the levels of some cytokines in mouse
temporal cortices. ELISAs were performed to quantify levels of
temporal cortex cytokines in vehicle and PPP (1mg/kg, 7 days)
treated wild type and AβPP/PS1 mice. Data are mean values
normalized to tissue wet weight ± SEM, *p<0.05 (n=6-8 animals),
(Fisher’s LSD test).
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Spleen Cytokine Levels Were Not Changed in
PPP Treated AβPP/PS1 Mice
In order to assess the effect of PPP treatment on peripheral inflammatory
markers, spleen cytokine ELISAs were also performed. Contrary to our
expectations, vehicle treated AβPP/PS1 mice had no elevation of spleen cytokine
levels compared to vehicle wild type mice suggesting that the proinflammatory
changes are selective for the brain in the AD mice (Fig. II-9). In addition, PPP
treatment had no effect on the concentrations of any cytokines in either strain
suggesting that the immunomodulatory effect of IGF-1R inhibition was unique to
the brain in these mice (Fig. II-9).
IGF-1R Stimulation via IGF-1 and Aβ Combination Altered
Microglial TNF-α Secretion in vitro
Based upon our data, the IGF-1R inhibitor dramatically modified microglial
phenotype and cytokine levels in the AβPP/PS1 brains. To test the idea that the
effects of IGF-1R inhibition we observed were mediated by primarily altering
microglial activation behavior, we examined the effect of prolonged IGF-1
stimulation on microglial phenotype. Microglia derived from postnatal day 0-3
cultures were stimulated for 7 days with IGF-1 to model prolonged IGF-1R
stimulation in vivo. IGF-1 pre-conditioned microglia did not differ in their ability to
phagocytose Aβ fibrils or bacterial bioparticles when compared to untreated
microglia (Fig. II-10A).

50

Figure II- 9.

IGF-1R inhibitor treatment exerted no effect on cytokine levels in
the spleens of AβPP/PS1 mice. ELISAs were performed to
quantify levels of cytokines in spleen lysates from the vehicle or
PPP (1mg/kg, 7 days) treated WT and AβPP/PS1 mice. Data are
mean values normalized to tissue wet weight ± SEM, *p<0.05,
(n=5-7 animals), (Fisher’s LSD test).
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Figure II- 10.

Microglia exposed to prolonged IGF-1 stimulation did not have
altered phagocytosis but increased cytokine secretory ability
when exposed to Aβ42. Microglia were stimulated in serum
containing media with 100ng/mL IGF-1 for 7 days replacing the
media every 2 days. The microglia were then stimulated an
additional 24 h with or without 100nM Aβ42 or 100ng/mL IGF-1 in
serum free media. A) 1µM FITC-Aβ42 or 0.25mg/mL FITC E. coli
bioparticle positive control were added to the cells for 6 h to
assess phagocytic uptake. B) TNF-α secretion was quantified via
ELISA from the media. C) Alternatively, cell viability was
assessed via an MTT assay. Graphs are means values ± SEM,
*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001, (n=3),
(Fisher’s LSD test).

In addition, IGF-1 pre-treatment had no effect on basal TNF-α secretion
but did significantly increase Aβ-stimulated TNF-α secretion compared to IGF-1
pretreatment alone or Aβ stimulation alone (Fig. II-10B). Similarly, IGF-1
pretreated microglia had significantly increased mitochondrial dehydrogenase
activity as assessed by an MTT assay when co-stimulated with Aβ peptide
compared to IGF-1 pretreatment alone or Aβ stimulation alone (Fig. II-10C). This
data demonstrated that prolonged IGF-1R stimulation altered microglia behavior
only in the presence of a concomitant Aβ stimulation.
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CHAPTER III
A PROTOCOL FOR MAKING AND SECTIONING MULTIPLE EMBEDDED
SWISS-ROLLS IN A GELATIN MATRIX
Introduction
Chapter II summarized proof-of-concept findings demonstrating that
modulating effects of a peripheral stimulus, IGF-1, could affect the brain in AD
mice. Based upon this, the overall project goals shifted to focus on peripheral
inflammatory conditions as potential stimuli to the brain during AD. In particular,
contributions of intestinal dysfunction on brain presentation of disease are the
remaining focus of the dissertation. In order to begin studying inflammatory
changes in the colon we elected to develop a medium throughput method for
visualizing staining throughout the entire mouse colon.
This Swiss-roll protocol was developed in order to examine histologic
changes following colonic disruption via utilizing either DSS or AOM/DSS
administration. The appropriate methodological approach for intestinal
preparation enables researchers to create representative histological and
immunostaining images which validate their biochemical data. The Swiss-roll
technique was first introduced by Reilly and Kirsner in 1965. Later, Moolenbeek
and Ruitenberg described a detailed procedure to longitudinally study the rodent
intestine in 1981 (Moolenbeek & Ruitenberg, 1981).
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In this protocol, our slightly different approach for co-embedding four
different Swiss-rolls in a gelatin block provides a full-length overview of crosssectional colons on a single slide. A single gelatin block is prepared by
simultaneously embedding at least four different intestinal Swiss-rolls. In addition,
the tissue orientation can be adjusted for each sample as desired which
facilitates the comparison of different colon samples on a single gelatin section.
Finally, the gelatin sections containing tissue samples are stable at least
overnight at room temperature for staining. The protocol allows for longitudinal
histologic examination of multiple tissue samples on a single slide
simultaneously. In this method, antigenicity is retained for immunohistology. In
addition, the accessibility of samples during the prolonged hardening time
required of the gelatin matrix allows the tissue samples to be adjusted/readjusted to provide the desired orientation and spatial arrangement for ideal
cross sections with similar planes of section and optimum space utilization for
slide mounting. In addition, the room temperature stability of the gelatin matrix
and the ability to contain numerous tissue samples in a block allows the flexibility
of performing thicker sections for free-floating tissue staining and ease of
mounting a single gelatin sheet rather than individual tissue sections. This is a
convenient approach for allowing precise preparation of multi-tissue blocks and
simultaneous sectioning, staining, and slide mounting of tissue for subsequent
comparisons (III-Graphical abstract).
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Methods
Materials
•

15% gelatin (Sigma, G2500-1KG) in PBS+ 0.02% Na Azide or 1:500 (from
10% stock)

•

4% paraformaldehyde (PFA)

•

15% and 30% sucrose in PBS + 0.02% Na Azide or 1:500 (from 10%
stock)

•

Swiss-roll intestines

•

Immunohistochemistry (IHC) solution containing 0.5% bovine serum
albumin (BSA, Equitech-Bio, Inc.), 0.1% Triton X-100 (Sigma-Aldrich), 5%
normal goat serum (NGS, Equitech-Bio, Inc.), and 0.02% Na Azide in
PBS.

Mice
Mice were euthanized followed by cardiac perfusion. Animal protocol was
reviewed and approved by the UND Institutional Animal Care and Use
Committee (UND IACUC). The investigation conforms to the National Research
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Council of the National Academies Guide for the Care and Use of Laboratory
Animals (8th edition).
Swiss Roll Preparation
1.

After euthanizing a mouse, forceps were used to pull up the abdomen at
the midline and make a V-shaped incision using surgical scissors.

2.

The incision was extended by cutting the skin along with peritoneum from
the pelvis toward the anus.

3.

The colon was located and surgical scissors were used to carefully cut it
out from the cecum toward the distal colon.

4.

The colon was removed from the peritoneal cavity and surgical scissors
used to remove the cecum.

5.

Surrounding fat tissue was removed from the remaining colon using
forceps.

6.

Feces were gently washed from the colon in a proximal to distal direction
using a gavage needle and syringe filled with cold PBS.

7.

The colon was held using fine-tipped forceps and cut longitudinally from
the distal to the proximal end using fine-tipped scissors.

8.

With the luminal side upward the colon was picked up by the distal end via
fine-tipped forceps and wrapped around one end of a toothpick.

9.

The colon was wrapped around the toothpick from the distal to the
proximal end by holding both ends of the toothpick with fingers and gently
rolling.
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10.

Once the roll was finished, a few drops of PBS were added onto the fine
end of the toothpick and the role was gently slid toward the fine end of the
toothpick to release the Swiss-roll.

11.

Holding both sides of the roll with blunt end forceps a 27G1/2 needle was
pushed through the roll.

12.

The roll was fixed in place by bending the sharp end of the needle using
blunt end forceps. This method was obtained from Whittem et al with
some modifications (Whittem, Williams, & Williams, 2010).

13.

The Swiss-roll was transferred to a 5 mL microcentrifuge tube filled with
4% PFA and store at 4°C for 5 days.

14.

The PFA was replaced with 30% sucrose on the 5th day. This step was
repeated one more time after four more days. The tubes were stored at
4°C in 30% sucrose until ready to make the gelatin block.

15.

Once the rolls were ready, they were embedding into a gelatin block (K.
Nagamoto-Combs, G. D. Manocha, K. Puig, & C. K. Combs, 2016).

16.

To make the blocks, 15% gelatin in PBS with 0.02% Na Azide was prewarmed (30-40°C) then dissolved at 40-42°C in a shaking incubator set on
high speed until the gelatin went into solution completely.

17.

The bottom of a petri dish was labeled using a permanent Sharpie marker.
1/3 of the petri dish was filled with the gelatin solution and allowed to cool
down to room temperature for 10 minutes. The dish was transferred to 4°C
for 10-20 minutes to completely solidify. This thin layer of gelatin in the
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petri dish provided a level stage to stick multiple (4 to 6) different samples
upright in order to have roughly identical sections/regions of all tissues on
a single slide for future comparison.
18.

After completing cryoprotection, the Swiss-rolls were removed from the
sucrose and the needle removed using blunt end forceps to straighten the
tip to allow the needle to be removed.

19.

The Swiss-rolls were dabbed on a Kimwipe to remove any extra sucrose.

20.

The rolls were then soaked in a well (e.g. use a 6 or 12 well plate)
containing a 15% fresh gelatin solution and allowed to equilibrate in the
oven at 40°C for 20-30 minutes.

21.

The petri dish was brought to room temperature and Swiss-rolls were
transferred from the gelatin solution to the petri dish using blunt end
forceps. The flat side of the rolls were placed onto the gelatin in the petri
dish. 4 or more Swiss-rolls were used per gelatin block.

22.

The rolls were allowed to stick onto the gelatin surface for 2-3 minutes at
room temperature, adjusting tissue orientation as needed.

23.

The petri dish was set atop a flat rack, which previously was pre-cooled at
-20°C, containing an ice pack. The gelatin block making procedure was
done on a laboratory bench at room temperature. The cold surface cooled
down the gelatin-soaked samples, keeps them upright and attached to the
gelatin bottom layer, and prevents the bottom gelatin layer from melting
and releasing the Swiss-rolls as they are covered with warm gelatin
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solution in the following step. The gelatin solution was next removed from
the oven to cool down a bit for about 5 minutes prior to adding to the rolls.
Gelatin solution was added dropwise onto each roll to just cover them
(Fig. III-1) and allowed to solidify for ~ 2 minutes, again adjusting tissue
orientation as needed.

Figure III- 1.

24.

Four colon Swiss-rolls were placed into a petri dish containing a
thin layer of 15% gelatin solution sitting atop an ice pack chilled
surface. After 2-3 minutes, additional gelatin solution was added
dropwise to gradually cover each roll.

Warm gelatin solution was gently poured on top of the rolls until they were
covered to almost half of their height without making bubbles (Fig. III-2).
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Figure III- 2.

25.

Gelatin solution was added gently to the petri dish atop the ice
pack chilled surface until the rolls were covered halfway. A) Side
and B) overhead images are shown.

After approximately 2 minutes, the rolls were carefully covered with
additional gelatin solution and ice packs were placed on both sides of the
petri dish and it was allowed to cool for about 20 minutes (Fig. III-3). The
cold surface cooled down the bottom of the petri dish. The ice packs on
both sides of the petri dish helped cool down the newly added gelatin
layer. An optimal cold environment around the petri dish accelerated the
solidification of the block and prevented the fixed Swiss-rolls from
becoming detached during the addition of warm gelatin. However, if the
area around the petri dish was too cold, subsequent gelatin layers could
not appropriately merge into a single layer.

26.

The petri dish was transferred to 4°C for 30 minutes to fully solidify.
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Figure III- 3.

27.

Additional gelatin solution was added until all four Swiss-rolls
were completely covered and allowed to partially solidify for 20
minutes. atop the ice pack chilled surface. The petri dish was
transferred to 4°C for 30 minutes to allow the gelatin solution to
fully solidify.

The cooled gelatin block was trimmed when solidified. A spatula was used
to pry out the solidified gelatin from the petri dish. The block was placed
onto a smooth surface and extra gelatin was carefully trimmed away using
a long blade and a slide (25x75x1mm) to make the required block size
(Fig. III-4).
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Figure III- 4.

28.

The solidified gelatin was A) removed from the petri dish and B)
trimmed to the same size as a double-subbed 25x75x1mm slide.

The trimmed gelatin block was fixed in 4% PFA for 24 hours. The fixative
solution covered the gelatin block completely. The PFA was replaced with
15% sucrose for another 24 hours. The block was stored at 4°C in a
plastic specimen container or a collection cup which was slightly larger
(approximately 5X as large as the block) than the gelatin block.

29.

The gelatin block remained in sucrose at 4°C until it sank to the bottom of
the 15% sucrose container.
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30.

The 15% sucrose was replaced with 30% sucrose for another 48 hours.
The 30% sucrose was replaced with one more 30% sucrose incubation for
an additional 48 hours until the block sank. The fully cryoprotected block
was then ready to be sectioned.

Swiss Roll Sectioning
1.

In order to section the block using a chambered cryostat (e.g. LEICA
CM1850), the gelatin block was first dried off with a Kimwipe to remove
any excess sucrose solution then transferred to a styrofoam container
containing crushed dry ice and 2-Methylbutane (Fisher Chemical, 95%
minimum) to freeze the block. To avoid cracks from forming in the block it
was preferable to not keep it in the dry ice-2-Methylbutane mixture for
greater than 10-20 seconds depending on the size of the gelatin block.

2.

Once the block was frozen evenly, optimal cutting temperature (OCT)
compound was used to adhere the block onto the cutting stage at -20°C
inside a cryostat.

3.

The frozen block was sectioned using a microtome knife (e.g. flat back
permanent knife 16 cm- profile c- steel, Leica Biosystems Nussloch
GmbH, Order No. 14 0216 07100, made in Germany) at -27°C to -35°C for
10 micron thick sections and they were mounted onto double-subbed
slides (25x75x1mm) right away. To prevent the thin gelatin section from
rolling on the knife, a small paint brush was placed at the edge of the
newly sectioned tissue to hold on to it while sectioning was being
completed. This step helped keep the thin gelatin section containing the
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tissue to stay stretched out and facilitated mounting the section onto the
slide.
A traditional chambered cryostat was used for sectioning 10 microns due
to its adjustable temperature which keeps the section frozen during the
sectioning and mounting steps. A sliding microtome (e.g. LEICA
SM2000R) can be used for thicker sectioning (40 microns) which is
appropriate for free-floating tissue staining as in our prior work using
brains (K. Nagamoto-Combs et al., 2016). We have also used the Swissroll gelatin matrix approach to make mouse heart and lung blocks for
mounted staining.
4.

The hardened gelatin blocks are stable at 4°C. Although we typically store
the mounted slides at -20°C, they are stable overnight at room
temperature before starting the staining.

Histologic and Immunostaining
1.

For H&E and Alcian blue staining, the slides were first removed from 20°C and allowed to dry at room temperature or in front of a fan for at
least 1 hour or 30 min, respectively. The tissues were then hydrated by
successive incubations in 95%, 75% alcohol, and distilled water, 5-7 dips
each.

2.

To demonstrate utility of the gelatin embedded section for histologic stains
we performed H&E staining. The slides were stained with Hematoxylin
(HARRIS HEMATOXYLIN, American MasterTech Scientific) for 5 minutes,
rinsed in tap water, followed by 2 dips in hydrochloric acid 1N solution
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(Fisher Chemical) for differentiation of the color, and a final rinse in tap
water. The sections were then blued in the 28-30% ammonium hydroxide
(NEWCOMERSUPPLY) for 5-10 seconds and rinsed thoroughly with tap
water. The slides were then rinsed in 75% alcohol for a minute followed by
30-50 seconds in Eosin (AQUEOUS EOSIN Y, American MasterTech
Scientific) as a counterstain. The slides were dehydrated with incubations
in 95% alcohol, 100% alcohol (x2) for 3-5 dips each, and xylene (x3) for 1
minute each followed by coverslipping using Permount (Fisher Chemical)
(Fig. III-5).

Figure III- 5.

Representative H&E and Alcian blue staining of gelatin
embedded tissue sections are shown with digital images of the
A) entire slides, B) 1.25X magnification, and C) 4X magnification
to demonstrate the whole length of cross-sectioned colon
obtained by cutting the prepared blocks

65

3.

Alcian blue staining was performed by placing the slides in 3% aqueous
acetic acid for 3 minutes followed by 1% aqueous Alcian blue
(NEWCOMERSUPPLY kit) pH 2.5 for 20-30 minutes. The excess stain
was removed by rinsing the slides in tap water then distilled water. Then,
the slides were counterstained in Nuclear Fast Red stain (Kernechtrot) for
2-3 minutes and rinsed in distilled water thoroughly. The slides were
dehydrated in 95% alcohol and 100% alcohol 15-30 seconds (2 dips) each
and three times in xylene for 1 minute each before being coverslipped
using Permount (Fisher Chemical) (Fig. III-5).

4.

In order to validate that antigenicity was maintained in gelatin embedded
tissue sections, immunohistochemistry (IHC) was performed. The dried
slides were placed in a ProHisto antibody amplifier plate (PHI-AA1-1), a
plate which is divided into 12 boxes (1 slid per well), and rinsed twice with
PBS, 5 minutes each. Any type of plastic or glass microscope slide
staining jars would suffice and no rocking is needed for this staining. In
order to block endogenous peroxidase activity, tissue slides were
incubated in PBS containing 0.3% H2O2 (30% Hydrogen Peroxide in
water, Fisher BioReagents) for 5 minutes at room temperature. After
incubation in IHC solution for 30 minutes to 1 hour at room temperature to
block non-specific antibody binding, the primary antibody was added. The
tissue slides were immunostained using an anti-CD68 (rat anti-mouse
antibody, 1:1000 dilution in IHC solution, MCA1957, BIO-RAD) antibody
overnight at 4°C. This macrophage marker antibody demonstrates robust
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intestinal immunoreactivity in our hands (K. L. Puig et al., 2015). On the
following day, the primary antibody was removed and the slides were
rinsed in IHC solution 4-5 times, 5-10 minutes each. The biotinylated
secondary antibody (rabbit anti-rat IgG antibody mouse adsorbed, 1:2000
dilution in IHC solution, BA-4001, Vector Laboratories, Inc.) was added for
2 hours at room temperature. VECTASTAIN Avidin-Biotin Complex (ABC,
Vector Laboratories, Inc.) kit was used to increase the detection sensitivity
of the biotinylated secondary antibody. The AB solution (1:500 dilutions
each) was prepared in PBS and incubated for 30 minutes at room
temperature before use. After removing the secondary antibody, the slides
were rinsed 2 times in IHC solution and 2 times in PBS, 5 minutes each.
The AB solution was added for 2.5 hours at room temperature followed by
4 rinses in PBS, 5 minutes each. To visualize the immunoreactivity, the
Vector VIP Peroxidase (HRP) Substrate kit (SK-4600, Vector laboratories,
Inc., Burlingame, CA) was used according to manufacture protocol. Vector
VIP Substrate develops a purple color after reacting with peroxidase
(HRP) enzyme. The images were taken using an upright Leica DM1000
microscope and Leica DF320 digital camera system (Fig. III-6).
As can be seen, it is feasible to simultaneously stain and mount a
minimum of 4-6 different tissues in a single block as well as mount 2 different
blocks containing the same or different treatments on a single standard
microscope slide (25x75x1mm). This simultaneous IHC processing allows us to
decrease reagent use, reduce variability in staining intensity across samples, and
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improve tissue comparisons across samples during subsequent analysis. Most
importantly, developing this method allowed us to proceed with studying
intestinal inflammatory conditions such as colitis and CAC in mice.

Figure III- 6.

Representative CD68 immunoreactivity of gelatin embedded
tissue sections are shown with digital images of A) a whole slide
containing two gelatin sections, 4 samples each, B) 1.25X
magnification, C) 4X magnification, D) 10X magnification, E) 20X
magnification, E) 20X magnification, and F) 40X magnification
images to confirm that our protocol does not attenuate CD68
antigenicity. Boxes demarcate image areas displayed in higher
magnification images.
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CHAPTER IV
GUT INFLAMMATION INDUCED BY DEXTRAN SULFATE SODIUM
EXACERBATED Aβ PLAQUE DEPOSITION IN THE APPNL-G-F MOUSE MODEL
OF ALZHEIMER’S DISEASE
Introduction
Alzheimer’s disease (AD) is a progressive age-related neurodegenerative
disorder. Besides extracellular Aβ plaque deposition and intracellular
neurofibrillary tangles, neuroinflammation plays a pivotal role in the susceptibility,
onset, and progression of AD ("2016 Alzheimer's disease facts and figures,"
2016; Anand, Gill, & Mahdi, 2014; Beach et al., 1989; Glenner & Wong, 1984b;
Itagaki et al., 1989b; H. R. Kim et al., 2019; Kinney et al., 2018; Kohler et al.,
2016; Masters et al., 2015; Mosher & Wyss-Coray, 2014; Nichols et al., 2019;
Querfurth & LaFerla, 2010; Terry, 1963). Numerous retrospective studies
demonstrate a significant reduction in the risk of AD in correlation with prolonged
use of non-steroidal anti-inflammatory drugs (NSAID) early in life (Etminan, Gill,
& Samii, 2003; in t' Veld et al., 2001; J. Wang et al., 2015; C. Zhang, Wang,
Wang, Zhang, & Zhang, 2018). A midlife elevation of inflammatory markers due
to systemic inflammation was also associated with increased cognitive decline
over the course of 20 years in older adulthood in a longitudinal human study
(Walker, Gottesman, et al., 2019). Observational studies demonstrated that
individuals with one or more major infections, including pneumonia, during midlife
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or later adulthood were exposed to higher risk of diminished brain volumes,
dementia, and AD pathology hallmarks (Walker, Ficek, & Westbrook, 2019).
In addition to the central nervous system being affected by aging, elderly
frequently suffer from gastrointestinal inflammation and dysfunction, including
fecal incontinence, constipation, microscopic colitis, and diarrhea (Camilleri,
Cowen, & Koch, 2008; Holt, 2001; Leung & Rao, 2009; Roach & Christie, 2008;
Schuster, Kosar, & Kamrul, 2015; van Hemert, Skonieczna-Żydecka, Loniewski,
Szredzki, & Marlicz, 2018). Indeed, inflammatory bowel disease (IBD), including
colitis and Crohn’s disease, is associated with the risk of developing cognitive
impairment, anxiety, and depression in patients (Attree et al., 2003; Castaneda,
Tuulio-Henriksson, Aronen, Marttunen, & Kolho, 2013; Dancey, Attree, Stuart,
Wilson, & Sonnet, 2009; Kurina et al., 2001; Navabi et al., 2018; van
Langenberg, Yelland, Robinson, & Gibson, 2017). This relationship may be due
to the fact that the gastrointestinal (GI) tract bi-directionally communicates with
the brain via the well-established gut-brain axis, including direct neuronal
communication, endocrine signaling markers, and the immune system (Westfall
et al., 2017). In our prior work we have shown intestinal changes in both human
AD and mouse models that correlate with changes in the brains supporting the
notion that brain and intestinal changes may be linked during disease (G. D.
Manocha et al., 2019; K. L. Puig et al., 2015). The human GI tract harbors 100
trillion microbes, 10 times more than total cells in the human body, which mostly
reside in the colon and play a critical role in regulating intestinal function (Khanna
& Tosh, 2014). Dysbiosis, changes in intestinal microbial diversity, have been
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reported in both human and animal models of IBD (Casén et al., 2015; Emge et
al., 2016; Frank et al., 2007; Halfvarson et al., 2017; Jang et al., 2018; Putignani
et al., 2016; S. L. Wang et al., 2019; Zuo & Ng, 2018) and Alzheimer’s disease
alike (Shen, Liu, & Ji, 2017; Vogt et al., 2017; L. Zhang et al., 2017) again
suggesting a gut-brain connection during disease. Most importantly, intestinal
inflammation in IBD mouse models results in microglial activation, altered
neurogenesis, and increased cortical inflammation (Han et al., 2018; Riazi et al.,
2008; Zonis et al., 2015).
In this study, we tested the hypothesis that induction of moderate colonic
inflammation potentiates the progression of AD through inflammatory changes
propagated from the intestine to the brain. Wild type and AppNL-G-F mice were
orally treated with 2 cycles of 2% dextran sulfate sodium (DSS) for 3 days
followed by a 14 day interval. Mice were assessed for changes in memory and
anxiety-like behavior during the second recovery phase and sacrificed 20 days
after the last DSS exposure to investigate the long-lasting impact of gut
inflammation on AD mouse brains. Our data demonstrated that chronic DSS
administration decreased locomotion activity but not memory function and
increased Aβ plaque load correlating with decreased microglial phagocytosis
phenotype in the AD mouse model.
Methods
Animals
AppNL-G-F mice (KI:RBRC06344) were obtained from Dr. Takashi Saito and
Dr. Takaomi C. Saido, RIKEN BioResource Center, Japan. These mice carry the
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humanized Aβ region, including Swedish (NL), Arctic (G), and Beyreuther/Iberian
(F) mutations which promotes Aβ production, enhances Aβ aggregation through
facilitating oligomerization and reducing proteolytic degradation, and increases
Aβ42/40 ratio, respectively (Saito et al., 2014). This transgenic mouse model of AD
develops cortical Aβ amyloidosis as early as 2 months. To perform this study,
wild-type (WT) C57BL/6 mice originally purchased from the Jackson Laboratory
(Bar Harbor, Maine) and the AppNL-G-F transgenic mice were maintained, as a
colony, under standard housing conditions including a 12 h light:12 h dark cycle
and 22 ± 1°C temperature with ad libitum access to food and water at the
University of North Dakota Center for Biomedical Research. Only male C57BL/6
control WT and AppNL-G-F mice at 6-10 months of age (n = 9-11 per treatment
group) were used due to limited animal availability (Table IV-1). Mice were
randomly divided into vehicle and DSS treated groups for 9 weeks of
investigation. Mice were euthanized followed by cardiac perfusion and the brain,
spleen, and colon were collected to quantify histologic and biochemical changes
on week 9. All procedures involving animals were reviewed and approved by the
UND Institutional Animal Care and Use Committee (UND IACUC). The
investigation conforms to the National Research Council of the National
Academies Guide for the Care and Use of Laboratory Animals (8th edition).

72

Table IV- 1. Animal numbers and age at the beginning of the experiment
Gender

Genotype

Male

Wild Type
Vehicle (n=9)
AppNL-G-F Vehicle
(n=10)

Male

Age at the
beginning of the
Experiment
7-8 month-old
9-10 month-old

Genotype

Wild Type DSS
(n=11)
AppNL-G-F DSS
(n=10)

Age at the
beginning of the
Experiment
6-7 month-old
10 month-old

Dextran Sulfate Sodium (DSS) Exposure and Assessment of the Severity of
Colitis-Like Symptoms
In order to mimic the effect of gut inflammation on the progression of AD in
adulthood, 6-10 months-old male AppNL-G-F mice and matched age and sex wild
type mice were randomly divided into 4 experimental groups (Table IV-1). Each
genotype was treated with vehicle (autoclaved drinking water) or 2% dextran
sulfate sodium (DSS) for 2 cycles, 3 days each, with a 14 day interval for
recovery before initiation of the second DSS exposure as described in Fig. IV-1
(Wirtz et al., 2017).
Colitis-like disease was induced in two groups by dissolving DSS
(2%, w/v, MW=36-50 kDa, MP Biomedicals, LLC, Santa Ana, CA, USA) in
autoclaved drinking water. During the second cycle of the DSS treatment to the
end of the study, mice were weighed individually. Drinking water as well as food
intake were monitored during the second DSS bout. The disease activity index
(DAI) is associated with the presence of gut lesions and inflammation and
represents the percentage of body weight loss, stool consistency, and the
presence of gross bleeding in feces. A Hemoccult test kit (Beckman Coulter Inc.,
CA, USA) was used to determine occult blood in the stool samples. DAI was
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Figure IV- 1.

Schematic of the experimental design and timeline of DSS
treatment and different assessments. 2% DSS was dissolved in
the drinking water and fed ad libitum to male C57BL/6 wild type
and AppNL-G-F mice (AD mouse model) at 6-10 months of age for
two cycles of three days each. DAI was scored from 1 day pre
exposure to 2 days post exposure during the second bout of
DSS treatment. The percentage of body weight loss was
calculated starting from the second DSS treatment untill the
week of euthanasia. On week 7, 12 days after exposure of DSS,
mice were tested for behavioral functions. On the following week,
brain, colon, and spleen tissues were collected in order to
examine the effect of gut integrity disruption during the
inflammation resolving phase.

evaluated and scored in a blinded fashion at 1 day prior to DSS treatment
(day 0), during the second cycle of 2% DSS administration, and 2 days post
exposure, totaling 5 days, as previously described with slight modifications
(Table IV-2) (Chassaing, Aitken, Malleshappa, & Vijay-Kumar, 2014b; Cooper,
Murthy, Shah, & Sedergran, 1993; Eichele & Kharbanda, 2017; Ghia,
Blennerhassett, Kumar-Ondiveeran, Verdu, & Collins, 2006; Snider et al., 2016).
Each parameter was scored on a scale of 0-4 and summed to get a score
out of 12 for the maximum DAI per mouse for each condition. The daily DAI per
mouse was subtracted from its respective day 0 to get the normalized score.
Body weight loss was calculated as the percentage ratio by dividing the body
weight on each specific day to the body weight on day 0 during the second cycle
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Table IV- 2. Disease activity index (DAI) scoring performed to assess the colitis
induced by DSS
Score

Weight loss (%)

Stool Consistency

Occult/gross bleeding

0
1
2

WI <1 %
1% ≤ WI < 5%
5% ≤ WI < 10%

Normal
Loose stools

Normal
+
++

3
4

10% ≤ WI < 20%
WI ≤ 20%

Diarrhea

+++
Gross bleedings

of 2% DSS administration until the week of mice collection (Fig. IV-1). The
method of scoring is quite analogous to clinical symptoms observed in human
IBD. Mice were approximately 8-12 months of age at the time of collection. On
the 8th week, animals were euthanized via CO2 asphyxiation followed by cardiac
perfusion with PBS. The colon weights and lengths between the cecum and
rectum as well as spleen weights were measured. The brain, colon, and spleen
were collected for further histochemical and biochemical analysis.
Behavioral Analysis: Open Field and Cross-Maze Tests
On the 7th week, open field (OF) and cross maze (CM) tests were
performed to assess the effect of DSS treatment on behavior during the second
recovery phase. Locomotor activity and working memory were evaluated by OF
and CM tests, respectively. To evaluate general locomotion associated with
treatment, animals were placed individually in the same quadrant of a 19cm ×
45cm × 25cm open field apparatus to freely explore and move for 10 min. The
distance traveled, time spent in the center of the field as well as time mobile were
scored by blind raters from video captured by Anymaze software (Stoelting Co.
Wood Dale, IL, USA). Following the test, the animals were placed back into their
home cages for at least 30 min prior to the next behavior assessment.
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CM testing allows mice to explore a cross-shaped maze at their own
discretion without any added stress or motivation such as lights, sound, food
deprivation, etc. Mice were placed in the same arm of the CM and allowed to
move and choose other arms for 10 min. A choice was considered when all 4
feet were within an arm. The total entries were recorded and the number of
alternations was counted (defined as 4 consecutive entries into 4 different arms),
and % alternation for each mouse was calculated as follows, # alternations/(total
entries-3)x100, by personnel blinded to the study paradigm. Immediate re-entry
into the same arm, after exiting it, was not considered as an arm choice. The
chance alternation rate for this task is 22.2%. The test was performed using
Anymaze software (Stoelting Co. Wood Dale, IL, USA). After completion of the
test, mice were returned to their home cages until tissue collection.
Histological Staining of Colonic Tissue
On the day of collection, distal colons were made into Swiss-rolls, fixed in
4% paraformaldehyde (PFA) for 5 days, and cryoprotected via two successive
changes of 30% sucrose. The Swiss-rolls were embedded into gelatin blocks and
were serially sectioned using a chambered cryostat for 10µm thick sections.
Colon sections were stained for histology H&E (Hematoxylin and eosin) and
Alcian blue stains as described in detail previously (Sohrabi & Combs, 2019). An
upright Leica DM1000 microscope and Leica DF320 digital camera system were
used to capture images and figures were made using Adobe Photoshop
software.
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Immunohistochemistry (IHC)
Left brain hemispheres were fixed in 4% PFA for 5 days followed by
cryoprotection via two successive changes of 30% sucrose. Brains were
embedded in 15% gelatin and serially sectioned into 40µm sections using a
sliding microtome (K. Nagamoto-Combs et al., 2016). Sections were
immunostained using antibodies against Iba-1 (1:1000 dilution, rabbit, 01919741, Wako Chemicals USA, Inc., Richmond, VA, USA), CD68 (1:1000 dilution,
rat anti-mouse, MCA1957, Bio-Rad Laboratories, Inc., CA, USA), GFAP (1:1000
dilution, D1F4Q, rabbit mAb, Cell Signaling Technology, Inc., Danvers, MA,
USA), and β-Amyloid (1:500 dilution, D54D2, rabbit mAb, Cell Signaling
Technology, Inc., Danvers, MA, USA) to detect microglia, astrocytes, and Aβ
plaques, respectively. For Aβ immunostaining, antigen retrieval was required and
performed using 25% formic acid (Sigma-Aldrich) for 25 min at room temperature
prior to blocking (Burlingame, CA, USA). Immunostaining was performed for the
Swiss-rolls via using rat anti-mouse CD68 (1:1000 dilution, MCA1957, Bio-Rad
Laboratories, Inc., CA, USA) and anti-claudin-4 (1:500 dilution, ZMD.306, rabbit
pAb, Invitrogen/ThermoFisher scientific, Waltham, MA, USA) antibodies to target
the intestinal macrophages and tight junction proteins, respectively (Sohrabi &
Combs, 2019). Antigen retrieval was performed for claudin-4 immunostaining
using citrate antigen unmasking solution (1:100 dilution, H-3300, Vector
laboratories, Inc., Burlingame, CA, USA) for 40 min at 80°C prior to blocking.
Tissues were rinsed in PBS and blocked in PBS solution containing 0.5% bovine
serum albumin (BSA, Equitech-Bio, Inc.), 0.1% Triton X-100 (Sigma-Aldrich), 5%
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normal goat serum (NGS, Equitech-Bio, Inc.), and 0.02% Na Azide for at least 30
min. After 24 hr of incubating tissues with primary antibodies at 4°C, respective
biotinylated secondary antibodies were used, including rabbit anti-rat IgG
antibody mouse adsorbed and goat anti-rabbit IgG (Vector Laboratories, Inc.,
Burlingame, CA, USA). A VECTASTAIN Avidin-Biotin Complex (ABC) kit was
used followed by the Vector VIP Peroxidase (HRP) Substrate kit (SK-4600) to
visualize the antibody binding (Vector laboratories, Inc., Burlingame, CA, USA).
Images were taken using an upright Leica DM1000 microscope and Leica DF320
digital camera. Immunohistochemistry quantitation of temporal cortices and
hippocampi was performed from 3 serial sections per brain (n=8) via converting
the images to greyscale and calculating the mean optical density for each image
using Adobe Photoshop CS3 software.
Enzyme-Linked Immunosorbent Assay (ELISA)
On the collection day, right hippocampi and parietal cortices of brain
hemispheres and middle regions of the colons were isolated and flash frozen.
Hippocampi, parietal cortices, and middle colons were lysed in RIPA buffer (20
mM Tris, pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 1 mM EDTA, 1
mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.1% SDS,
and 0.5% deoxycholate), lysis buffer 17 (R&D Systems, a Bio-techne brand,
Minneapolis, MN, USA), and 1% Triton X-100 in PBS, respectively, with protease
inhibitor cocktail (P8340, Sigma-aldrich, MO, USA). Tissues were centrifuged
(12,000 rpm, 4°C, 10 min) and the supernatants were collected. Hippocampi
supernatants were used to perform soluble Aβ1-40/42 ELISAs (human Amyloid
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β40/42 Brain EZBRAIN40/42 ELISA, EMD Millipore, Billerica, MA, USA). The
hippocampi pellets were re-suspended in 5M guanidine HCL/50mM Tris HCL, pH
8.0, centrifuged (12,000 rpm, 4°C, 10 min), and the supernatants were removed
to quantify insoluble Aβ1-40/42 levels by using the same ELISA kit according to the
manufacturer’s protocol. TNF-α, IL-1β, and IL-6 cytokine ELISAs were performed
from the parietal cortices supernatants according to the manufacturer’s protocol
(Quantikine ELISAs, R&D Systems, a bio-techne brand, Minneapolis, MN, USA).
The collected colon supernatants were used to perform lipocalin-2 ELISA (Mouse
Lipocalin-2/NGAL DuoSet ELISA, R&D Systems, a bio-techne brand,
Minneapolis, MN, USA) according to the manufacturer’s protocol. The BCA kit
(Thermo Scientific, IL, USA) was used to quantify protein concentrations and Aβ,
lipocalin-2, and cytokine levels were normalized to the protein content of each
homogenized sample.
Western Blotting
Protein contents were assessed for the collected hippocampi
supernatants, previously lysed in RIPA buffer containing protease inhibitor
cocktail, via a BCA kit. 5 µg of protein per sample was resolved by 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene difluoride membranes (PVDF) for western blotting. Membranes
were blocked for 1h in 5% bovine serum albumin (BSA) in tris-buffered saline
solution (TBST) followed by applying anti-amyloid precursor protein (1:1000
dilution, Y188, ab32136, rabbit mAb, Abcam, Cambridge, MA, USA), BACE
(1:1000 dilution, D10E5, rabbit mAb, Cell Signaling Technology, Inc., Danvers,
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MA, USA), Cox-2 (1:500 dilution, Cyclooxygenase 2, rabbit pAb, ab15191,
Abcam, Cambridge, MA, USA), and VCAM-1 (1:1000 dilution, H-276: sc-8304,
rabbit pAb, Santa Cruz Biotechnology, Inc., CA, USA) primary antibodies
overnight at 4°C. Chemiluminescent visualization was used to detect antibody
binding using donkey anti-rabbit IgG and goat-anti mouse IgM horseradish
peroxidase (HRP)-conjugated secondary antibodies (Santa Cruz Biotechnology,
Inc., CA, USA). Exposures were captured using an Aplegen Omega Lum G
imaging system. Optical density values were normalized to the loading control αtubulin (1:10000 dilution, TU-02: sc-8035, mouse mAb, Santa Cruz
Biotechnology, Inc., CA, USA) optical density values from the same membrane.
Statistical Analysis
All in vivo data were analyzed by two-way ANOVA multiple comparisons
followed by Uncorrected Fisher’s LSD test using GraphPad Prism 8 software.
Data are represented as the mean ± SEM. Significance is indicated by P value
measurements with a P < 0.05 considered significant; *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
Results
DSS Induced Colitis-Like Symptoms in Wild Type and AppNL-G-F Mice
6-10 months-old male AppNL-G-F mice and matched age and sex wild type
mice were treated with 2% DSS for 2 bouts (Fig. IV-1) to induce colonic
inflammation. Symptomatic parameters of colitis, including DAI, % body weight
loss, colon length, and spleen and colon weights were monitored and recorded.
During the second administration of DSS, both wild type and AD mouse models
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displayed significantly greater disease activity scores and % body weight losses
compared to their respective untreated groups starting on days 1 and 4,
respectively (Fig. IV-2A and B).

Figure IV- 2.

DSS treatment induced symptomatic parameters of colitis-like
disease in both genotypes compared to controls. A) DAI was
monitored on day 0, during the second cycle of 2%DSS (3 days),
and 2 days post DSS exposure in both DSS and vehicle treated
groups per genotype. (**p<0.01, ****p<0.0001 wild type vehicle vs.
wild type DSS; ++p<0.01, +++p<0.001, ++++p<0.0001 AppNL-G-F
vehicle vs. AppNL-G-F DSS; $$p<0.01, $$$p<0.001 wild type DSS
vs. AppNL-G-F DSS comparing on the same day, mean ± SEM,
n=9-11 animals). B) the percentage of body weight changes was
calculated during the second DSS epxposure untill week of
tissue collection. (*p<0.05, ***p<0.001, ****p<0.0001 wild type
vehicle vs. wild type DSS; +p<0.05, ++++p<0.0001 AppNL-G-F
vehicle vs. AppNL-G-F DSS comparing on the same day, mean ±
SEM, n=9-11 animals). (C-D) Spleen and colon weights as well
as colon length were measured from wild type and AppNL-G-F
mice to indicate colonic inflammation. (*p<0.05, **p<0.01,
***p<0.001, mean ± SEM, n=9-10 animals).
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Wild type mice developed greater DAI compared to AppNL-G-F mice on
days 3-4 due to DSS treatment (Fig. IV-2A). Mice were expected to recover to
their initial weight during the course of recovery (Snider et al., 2016). However,
both wild type and AppNL-G-F DSS treated mice showed a consistent reduction in
body weight without complete recovery after ending the second cycle of DSS
exposure until euthanasia in comparison with their controls (Fig. IV-2B). Body
weight loss and rectal bleeding are associated with shortening and thickening of
the colon as well as splenomegaly, as other biological markers for assessment of
colonic inflammation (Chassaing et al., 2014b; Chassaing et al., 2012). The
2% chronic DSS treated group in both genotypes demonstrated a significant
increase in spleen and colon weights typically related to anemia as a result of
rectal bleeding (Chassaing et al., 2012) and the granulomatous nature of
inflammation (Chassaing et al., 2014b), respectively (Fig. IV-2C and D). Colonic
length significantly decreased in wild type but not AppNL-G-F mice after
inflammation induction (Fig. IV-2E). Overall, these results demonstrated that 2
cycles of chronic DSS treatment produced a time-dependent DAI in both wild
type and AppNL-G-F genotypes.
DSS Treatment Decreased Mobility of AppNL-G-F Mice
To determine whether induction of moderate colonic inflammation
negatively affects locomotor activity and working memory, wild type and AppNL-G-F
mice were examined in the open field (OF) and cross maze (CM) paradigms
12 days after completing the second cycle of DSS, during the resolving
inflammation phase, respectively. The OF test examines general locomotion and
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anxiety-like behavior via primarily exploratory behavior (Crawley, 1985).
Interestingly, AppNL-G-F mice showed a greater distance traveled at baseline
compared to wild type mice in vehicle treated groups in the OF test. The
genotype-dependent increase in mobility as well as time mobile were attenuated
due to DSS administration in the AppNL-G-F mice. However, DSS exposure
exerted no effect on time spent in the center of the OF in both genotypes
(Fig. IV-3A). This suggests a basal increase in locomotion activity in AppNL-G-F
mice that had long-lasting attenuation following DSS treatment in AppNL-G-F mice.

Figure IV- 3.

DSS treatment decreased mobility of AppNL-G-F mice in both OF
and CM tests. A) General locomotor activity or anxiety-like
behavior was assessed by quantifying the distance traveled, time
spent in the center as well as time mobile using OF test. B) Total
entries (locomotion) and percentage of alternations in different
arms of the CM test were quantified to evaluate working memory
in both genotype vehicle and DSS treated groups. (*p<0.05,
**p<0.01, ***p<0.001, mean ± SEM, n=8-10 animals tested at 8-12
months of age).
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To assess the working memory changes induced by 2 bouts of 2% DSS
treatment, performance in the CM paradigm, which is a “+” shaped apparatus
with four white arms, was examined for both genotypes (B. Wang et al., 2017).
Consistent with the OF results, the total number of arm choices, indicating
locomotor activity, was greater in vehicle treated AppNL-G-F mice compared to the
wild type control group. The total entries were reduced in AppNL-G-F mice after
DSS administration (Fig. IV-3B). As we expected, a significant reduction was
observed in the % alternations made by the AppNL-G-F vehicle treated group in
comparison with the wild type controls suggesting the presence of baseline
memory deficit in this mouse model of AD. However, there was no significant
decrease in % alternations due to DSS treatment (Fig. IV-3B). This is likely due
to the fact that the alternation rate (%) representing working memory was
calculated as the number of alternations divided by (total entries-3)x100 for each
mouse, while total entries (locomotion) significantly decreased in AppNL-G-F DSS
treated mice. These findings indicated that DSS exposure negatively affected
AppNL-G-F mice locomotion in a persistent fashion during the second recovery
phase.
DSS Administration Disrupted Colonic Epithelial Integrity
and Increased Inflammation
In order to perform histological examination of colonic inflammation
induced by DSS, H&E and Alcian blue staining were performed on the distal
colon Swiss-rolls (Fig. IV-4A). Hematoxylin and eosin staining showed minimal
hyperplasia or crypt elongation (an increase in epithelial numbers in longitudinal
crypts relative to baseline epithelial cell numbers per crypt), mixed leukocytes
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Figure IV- 4.

DSS treatment resulted in colonic inflammation in both wild type
and AppNL-G-F mice. A) H&E and Alcian blue staining along with
anti-CD68 and claudin-4 immunostaining of cross sectional
Swiss-roll sections of the distal colon were performed to examine
the severity of epithelial erosion, loss of goblet cells, infiltration of
macrophages, and changes of the tight junction levels in colon
sections of DSS treated vs. vehicle groups in both genotypes
(n= 4 Swiss-rolls/condition/genotype). B) The changes in
lipocalin2 levels, as an anti-microbial siderophore-binding
peptide involved in IBD, were assessed to determine the extent
of intestinal inflammation in both wild type and AppNL-G-F mice
following DSS exposure. (**p<0.01, ****p<0.0001, mean ± SEM,
n=8 animals).

infiltration, goblet cell loss, and to some extent erosion (i.e. loss of surface
epithelium), ulceration (epithelial defect reaching beyond muscularis mucosae),
and crypt loss (musoca devoid of crypts) in both DSS treated groups compared
to their controls (Fig. IV-4A) (Erben et al., 2014). To better assess goblet cell loss
caused by chronic DSS exposure, mucin-producing goblet cells were visualized
by performing Alcian blue staining. Alcian blue stains acidic mucus secreted by
goblet cells (G. G. Adams & Dilly, 1989). Wild type and AppNL-G-F DSS treated
mice demonstrated reduced staining of goblet cells compared to their controls
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(Fig. IV-4A). It has been reported that the number of CD68 positive macrophages
increases in colon specimens of IBD patients compared to normal individuals
(Rugtveit, Brandtzaeg, Halstensen, Fausa, & Scott, 1994). Therefore, CD68
immunostaining was performed to visualize infiltrating, activated macrophages,
into the lamina propria and colonic submucosa. As expected, a robust increase in
macrophage infiltration to the site of inflammation was observed in both DSS
treated genotypes in comparison with controls (Fig. IV-4A). Claudin proteins, tight
junction proteins that regulate paracellular permeability, undergo changes in
expression levels and distribution in IBD (Perše & Cerar, 2012). Claudin-4
staining decreases or redistributes in surface epithelial areas of IBD biopsies
compared to its strong expression in normal colonic epithelium (Prasad et al.,
2005). Immunohistochemistry staining showed a dramatic reduction in claudin-4
immunoreactivity of tight junction areas in the surface epithelium in wild type and
AppNL-G-F mice due to colonic inflammation compared to their controls
(Fig. IV-4A). Lipocalin-2 (Lcn2), a 25 kDa neutrophil gelatinase-associated
lipocalin (NGAL) glycoprotein, was first isolated from human neutrophil granules
(Kjeldsen, Cowland, & Borregaard, 2000). Fecal Lcn2 is a stable, highly
sensitive, and non-invasive marker which determines the extent of intestinal
inflammation (Chassaing et al., 2012). Colonic lipocalin ELISA demonstrated
over 13 and 20-fold increases in response to DSS treatment in AppNL-G-F and wild
type mice compared to their controls, respectively (Fig. IV-4B). These findings
suggest that 2% chronic DSS administration induced mild to moderate intestinal
inflammation in both genotypes.
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Gut Inflammation Induced by DSS Exacerbated Aβ Accumulation in
AppNL-G-F Mice Brains
Wild type and AppNL-G-F mice were treated with 2 cycles of 2% DSS and
sacrificed 20 days (on week 8th) after the last exposure (Fig. IV-1) to assess longlasting brain changes. The impact of moderate disruption of gut epithelial barrier
and gut inflammation on Aβ deposition in different brain regions was assessed.
Aβ immunohistochemistry demonstrated that plaque load significantly increased
in both hippocampi and temporal cortices of AppNL-G-F mice in response to DSS
treatment compared to their controls (Fig. IV-5A and B).

Figure IV- 5.

DSS treatment elevated hippocampal and temporal cortex Aβ
levels in AppNL-G-F mice. A-B) Immunohistochemistry was
performed on both wild type and AppNL-G-F brains using anti-Aβ
antibody. Mean optical density was measured using 3 different
hippocampus sections/mouse. Representative hippocampi and
temporal cortices are shown. C) Hippocampi, collected from
vehicle and DSS treated wild type and AppNL-G-F mice, were
lysed to perform ELISAs for human insoluble Aβ1-40/42 and
soluble Aβ1-40/42. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001,
mean ± SEM, n=8 animals).
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Similarly, Aβ ELISA of hippocampi demonstrated more than 2-fold
increase in both insoluble Aβ1-40 and Aβ1-42 in DSS treated AppNL-G-F mice in
comparison with the vehicle treated group. Soluble Aβ1-40/42 showed no
statistically significant changes due to DSS administration, although there was an
increase trend in the DSS treated AppNL-G-F mice (Fig. IV-5C). These data
indicate that inducing moderate intestinal inflammation leads to exacerbation of
AD pathology via elevating Aβ plaque deposition as a maintained brain change
even during the resolution phase of gut inflammation.
Microglial Phagocytic Phenotype Decreased Due to the Moderate ColitisLike Symptoms Induced by DSS Treatment
It is well established that brain specialized inflammatory cells, microglia
and astrocytes, become activated and express inflammatory cytokines in various
brain diseases, including AD. Impaired microglial phagocytosis activity in
response to Aβ plaque deposition plays a hypothesized role in pathogenesis and
progression of AD (D. V. Hansen et al., 2018; Itagaki et al., 1989b; Nichols et al.,
2019; M. Prinz, J. Priller, S. S. Sisodia, & R. M. Ransohoff, 2011; W. Y. Wang, M.
S. Tan, J. T. Yu, & L. Tan, 2015). We expected that propagation of gut
inflammation induced by DSS to the brain would also affect brain gliosis
correlating with the elevated Aβ levels. Immunohistochemistry was performed to
investigate the impact of colonic barrier disruption and gut inflammation on glial
activation. Notably, astrocytosis, visualized using anti-GFAP immunoreactivity,
did not reveal any dramatic alterations following DSS administration in wild type
or AppNL-G-F hippocampi compared to their controls (Fig. IV-6). Microgliosis was
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Figure IV- 6.

DSS treatment reduced microglia CD68 immunoreactivity in
AppNL-G-F mice. Immunohistochemistry was performed on both
wild type and AppNL-G-F brains using anti-GFAP, Iba-1, and CD68
antibodies. Mean optical density was measured using 3 different
hippocampus sections/mouse. Representative hippocampi are
shown. (**p<0.01, ****p<0.0001, mean ± SEM, n=8
animals/condition).

assessed using two different antibodies, anti-Iba-1 and CD68. Interestingly,
moderate colonic inflammation diminished Aβ-associated microglial phagocytic
phenotype, demonstrated by CD68 immunoreactivity, in AppNL-G-F mice versus
their vehicle controls. Similar to GFAP, the motility-related microglial protein,
Iba-1, (Franco-Bocanegra, McAuley, Nicoll, & Boche, 2019) was not altered in
response to gut inflammation induced by DSS in both genotype hippocampi
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(Fig. IV-6). This suggested that moderate gut inflammation resulted in a selective
phenotype change in gliosis with no change in astrocytes but reduced microglial
phagocytic phenotype that correlated with increased Aβ plaque accumulation in
the brain.
DSS Treatment Did Not Change Brain Cytokine Levels
Parietal cortices were lysed and cytokines levels quantified by ELISA to
assess inflammatory cytokine profile changes, including TNF-α, IL-1β, and IL-6,
as a result of 2 cycles of 2% DSS treatment in both wild type and AppNL-G-F mice.
The brain levels of TNF-α were below detection level and IL-1β levels were not
changed across experimental groups and genotypes (data not shown). As
expected, vehicle treated AD mice demonstrated significantly higher IL-6 levels
compared to their wild type control. The cytokine levels were not significantly
elevated by DSS treatment in wild type and AppNL-G-F mice compared to controls,
however (Fig. IV-7). This finding suggests that moderate gut inflammation does
not lead to long-term effects on brain IL-6 levels.
DSS Treated AppNL-G-F Mice Brains Demonstrated Changes in
Neurodegeneration and Neuroinflammatory Markers
Based upon the changes in Aβ plaque load and microglial phenotype, we
next investigated the changes in levels of proteins involved in Aβ processing,
inflammation, and vascular phenotype in the mouse brains 20 days following the
DSS treatments via western blots. Hippocampi lysates were used to quantify
APP and BACE (β-secretase) protein levels, two proteins required for
Aβ production in AD. No increases were observed in APP protein levels due
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Figure IV- 7.

Brain IL-6 levels did not change due to DSS treatment. Parietal
cortices collected from vehicle and DSS treated wild type and
AppNL-G-F mice and were lysed to quantify protein levels of IL-6
by ELISA. (*p<0.05, mean ± SEM, n=8 animals).

to gut inflammation in either genotypes. However, DSS exposure increased βsecretase protein levels in AppNL-G-F mice compared to the wild type group
consistent with our Aβ ELISA and immunohistochemistry results showing
elevated Aβ levels and plaque deposition after DSS treatment (Fig. IV-8). Protein
levels of cyclooxygenase-2 (cox-2), an inflammatory marker, and vascular cell
adhesion molecule-1 (VCAM-1), a mediator of leukocyte binding and
transmigration through endothelial cells during inflammation, (Chung et al., 2010;
Cook-Mills, Marchese, & Abdala-Valencia, 2011) were also elevated in AppNL-G-F
mice compared to the wild type group due to DSS exposure (Fig. IV-8). These
results suggest that DSS treatment increased Aβ processing and vascular
reactivity in AppNL-G-F mice verifying that peripheral intestinal inflammation
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preferentially affects the brains of diseased mice and is maintained even during
the gut healing phase.

Figure IV- 8.

DSS treatment increased BACE, Cox-2, and VCAM-1 levels in
AppNL-G-F compared to wild type mice. A) Hippocampal lysates
from vehicle and DSS treated wild type and AppNL-G-F mice were
western blotted to B) quantify protein changes related to APP,
BACE, Cox-2, and VCAM-1 levels using α-tubulin as the loading
control. (*p<0.05, mean ± SEM, n=8 animals).
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CHAPTER V
EFFECT OF ALZHEIMER’S DISEASE ASSOCIATED APP MUTATIONS
ON THE PROGRESSION OF COLORECTAL CANCER INDUCED
BY AOM/DSS IN MICE
Introduction
Amyloid precursor protein (APP) along with APP-like protein 1 and 2
(APLP1 and APLP2) are members of the highly conserved APP family (Sprecher
et al., 1993; Wasco et al., 1993). Although APP is known for its critical
contribution in Alzheimer’s disease (AD) development and progression in the
central nervous system, it is expressed in many other cell types (Arai et al., 1991;
Golde et al., 1990; Nalivaeva & Turner, 2013; K. L. Puig & Combs, 2013;
Schlossmacher et al., 1992; Tang et al., 2003). APP and β-site APP cleaving
enzyme 1 (BACE1) are robustly expressed in brain tissue (Haass, Kaether,
Thinakaran, & Sisodia, 2012). In AD brains, APP is processed into soluble APPβ
(sAPPβ), the primary Aβ element of the neuritic plaques, and APP intracellular
domain (AICD) fragments via the subsequent cleavage of BACE1 and γsecretase in the amyloidogenic pathway. In the non-amyloidogenic pathway,
APP is cleaved by α-secretase (ADAM10) and γ-secretase to produce sAPPα,
P3, and AICD sequences (Cole & Vassar, 2007; Gandy, Caporaso, Buxbaum,
Frangione, & Greengard, 1994; Y. Li, Zhou, Tong, He, & Song, 2006).
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Notably, APP/sAPP is upregulated in multiple cancers, including breast,
prostate, pancreatic, thyroid, colon, oral squamous cell carcinoma, and
melanoma (Botelho, Wang, Arndt-Jovin, Becker, & Jovin, 2010; Hansel et al.,
2003; Ko et al., 2004; Krause et al., 2008; S. Lim et al., 2014; Meng, Kataoka,
Itoh, & Koono, 2001; Pietrzik et al., 1998; Seguchi, Kataoka, Uchino, Nabeshima,
& Koono, 1999; Takagi et al., 2013; Takayama et al., 2009; Venkataramani et al.,
2010; Woods & Padmanabhan, 2013). The full-length APP and its soluble
proteolytic product, sAPPα, which is processed by the non-amyloidogenic
pathway promotes migration and proliferation of breast cancer cells in vitro and in
a xenograft in vivo model as well as in pancreatic cancer cells (Tsang et al.,
2018; Woods & Padmanabhan, 2013). Human colorectal adenocarcinoma cell
lines secrete sAPPα containing a Kunitz protease inhibitor domain as their
primary trypsin inhibitor (Seguchi et al., 1999). Inhibition of APP expression using
antisense RNA leads to suppression of human colon carcinoma cell growth in
vitro and in xenograft nude mice (Meng et al., 2001). Additionally, AICD, can
serve as a transcription factor to regulate protein synthesis both in primary and
cancerous human dividing cells (Sobol et al., 2015). A body of investigations
reveal an inverse link between AD and cancer in both human and mice (Ham et
al., 2018; Ibáñez et al., 2014; J. E. Lee et al., 2018; Musicco et al., 2013; Roe et
al., 2010; Sherzai et al., 2020).
To determine whether expression of APP or preferentially increased
metabolism of APP into Aβ and sAPPβ fragments might influence the
progression of cancer, we utilized a common colitis-associated colorectal cancer
94

(CAC) model which is slightly different than the dextran sulfate sodium (DSS)induced colitis-like model in our previous study. In addition, effects of this
additional model of intestinal inflammation on brain Aβ deposition were
assessed. Both male and female C57BL/6 wild type control, App-/-, and AppNL-G-F
mice at 5-8 months of age were treated with azoxymethane (AOM) and DSS to
model human colorectal cancer. We observed sex- and genotype-dependent
tumorigenesis and differentiation in our animal models. Notably, CAC also
increased the Aβ plaque load in the brains of only AppNL-G-F male mice.
Methods
Animals
Both male and female APP knockout mice (App-/-) strain B6.129S7Apptm1Dbo/J (https://www.jax.org/strain/004133), wild-type (App+/+) C57BL/6 mice,
and APP transgenic (AppNL-G-F) mice (KI:RBRC06344) were utilized in the
present investigation. App-/- and wild-type mice were originally purchased from
the Jackson Laboratory (Bar Harbor, Maine). AppNL-G-F mice were obtained from
Dr. Takashi Saito and Dr. Takaomi C. Saido, RIKEN BioResource Center, Japan
(Saito et al., 2014). The mouse App gene was inactivated via deletion of its
promoter, first exon, and the signal peptide of APP in App-/- mice (Zheng et al.,
1995). The inserted humanized Aβ region in AppNL-G-F mice carries Swedish (NL),
Arctic (G), and Beyreuther/Iberian (F) mutations which enhances Aβ production,
promotes Aβ aggregation through facilitating oligomerization and reducing
proteolytic degradation, and increases the Aβ42/40 ratio, respectively (Saito et al.,
2014). Animals were maintained as a colony, provided food and water ad libitum,
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and housed under standard conditions including a 12 h light:12 h dark cycle and
22 ± 1°C temperature at the University of North Dakota Center for Biomedical
Research. Due to limited animal availability, 6-11 male and female mice per
treatment group at 5-8 months-old were used to perform the experiment
(Table V-1).
Table V- 1. Animal numbers and age at the beginning of the experiment
Gender

Genotype

Age at the Time of
Saline
Injections

Male

Wild Type (n=11)

5–6 month old

Male

App-/- (n=8)

5–ؘ8 month-old

Male

AppNL-G-F (n=6)

Female

Wild Type (n=9)

5–6 month-old

Female

App-/- (n=9)

5–7 month-old

Female

AppNL-G-F (n=10)

5 month-old

5 month-old

Genotypes

Age at the
Time of AOM
Injections

Wild Type
(n=11)
App-/- (n=10)

5–6 month old

AppNL-G-F (n=6)

5 month-old

Wild Type
(n=11)
App-/- (n=11)

5–6 month-old

AppNL-G-F (n=10)

5 month-old

5–8 month-old

5–7 month-old

Each genotype per gender was randomly divided into vehicle (saline i.p.
injection and drinking water) and drug (AOM i.p. injection and dissolved DSS in
drinking water) treated groups for 17 weeks of investigation (Fig. V-1).
The brain, spleen, and colon were collected to quantify histologic and
biochemical changes after euthanizing animals by CO2 asphyxiation and
subsequent cardiac perfusion with PBS. All procedures involving animals were
reviewed and approved by the UND Institutional Animal Care and Use
Committee (UND IACUC). The investigation conforms to the National Research
Council of the National Academies Guide for the Care and Use of Laboratory
Animals (8th edition).
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Figure V- 1.

Schematic of the experimental design and timeline of AOM/DSS
treatment. Wild type, App-/-, and AppNL-G-F male and female mice
received 10mg/kg of AOM via i.p. injection on week 0. On week
1, the drug treated groups were exposed to 1.5% dissolved DSS
in autoclaved drinking water for 7 days. Vehicle groups received
saline intraperitoneally on week 0 and consumed the autoclaved
drinking water throughout the experiment. Mice were sacrificed
on week 17 and brains, normal and cancerous colon tissues as
well as spleens were collected for further histological and
biochemical assessments.

Induction of CAC via AOM/DSS Treatment
In order to induce CAC similar to humans, drug treated mice per genotype
per gender were intraperitoneally injected with AOM (10mg/kg, Sigma-Aldrich, St.
Louis, MO, USA) on day 0 (week 0) followed by exposure to dissolved DSS
(1.5%, w/v, MW=36-50 kDa, MP Biomedicals, LLC, Santa Ana, CA, USA) in
autoclaved drinking water starting on week 1 for 7 days. Vehicle control groups
only received saline i.p. injections on day 0 and consumed autoclaved water
throughout the study (Fig. V-1) (De Robertis et al., 2011; S. M. Lee et al., 2016;
Tanaka, Oyama, Sugie, & Shimizu, 2016). The average DSS consumption was
measured per mouse per day during the 7 days of exposure (Table V-2). During
the 17 weeks, mice were weighed once a week to monitor the weight changes,
except week 1 in which mice were maintained in isolated chambers due to the
carcinogenic nature of AOM. The %body weight changes was calculated by
dividing the mouse body weight per each week to its initial weight on week 0, as
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Table V- 2. DSS consumption dissolved in drinking water during 7 days of
exposures
Gender

Genotypes

Average DSS Consumption/Mouse/Day
For 7 Days (mL)

Male

Wild Type (n=11)

6.6

Male

App-/- (n=10)

5

Male

AppNL-G-F (n=6)

6.7

Female

Wild Type (n=11)

4.6

Female

App-/- (n=11)

4.5

Female

AppNL-G-F (n=10)

6

the percentage ratio. At the end of week 17 post-treatment, mice were collected
and the colon weights and lengths from the cecum to rectum as well as spleen
weights were measured. Tumor numbers were recorded following mouse
sacrifice from the proximal to distal colon. Tumor areas (mm2) were calculated,
as an average for each mouse, using Adobe Photoshop CS3 software (Adobe
Systems, San Jose, CA) from colon images that were taken on the day of
collection. For further biochemical and histological investigations, the brain,
normal and cancerous colon tissues, and spleens were collected.
Histological Staining and Scoring of Colonic Swiss-Rolls
After collecting tumors and normal adjacent tissues, the full-length colon
from proximal to distal were made into Swiss-rolls. Briefly, following 5 days of
fixation in 4% paraformaldehyde (PFA) and cryoprotection via two successive
changes of 30% sucrose, the Swiss-rolls were embedded into 15% gelatin
blocks. The blocks, after 4% PFA fixation and subsequent sucrose
cryoprotection, were serially sectioned into 10µm thick sections via a chambered
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cryostat. Hematoxylin and eosin (H&E) staining was performed to assess the
extent of inflammation in AOM/DSS treated animals (Sohrabi & Combs, 2019).
The stained sections were then examined by a pathologist blinded to the
experimental groups. CAC scores were assigned based on the extent and
severity of inflammation, mucosal hyperplasia, and dysplasia. Scoring methods
were as follow: A) inflammation score: 0= normal (within normal limits); 1= mild
(small, focal, or widely separated, limited to lamina propria); 2= moderate
(multifocal or locally extensive, extending to submucosa); 3= severe (transmural
inflammation), B) mucosal hyperplasia score: 0= normal (within normal limits);
1= mild (crypts 2-3 times normal thickness, normal epithelium); 2= moderate
(crypts 2-3 times normal thickness, hyperchromatic epithelium, reduced goblet
cells, scattered arborization); 3= severe (crypts ≥ 4 times normal thickness,
marked hyperchromasia, few to no goblet cells, high mitotic index, frequent
arborization), C) neoplastic transformation score: 0= normal; 1= low grade
dysplasia; 2= high grade dysplasia/adenomatous polyp; 3= Adenocarcinoma.
Both individual and sum of 3 histology scores were graphed for accurate analysis
of mice colonic Swiss-rolls.
Human colon normal and tumor frozen tissue array slides were purchased
from BioChain (Newark, CA, USA). H&E histological staining as well as antiAβPP Y188 (1:1000 dilution, Abcam, Cambridge, MA, USA) immunostaining
were performed to assess APP expression.
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All stained slides were scanned using a Hamamatsu 2.0HT digital slide
scanner and figures were made using Adobe Photoshop CS3 software (Adobe
Systems, San Jose, CA).
Brain Immunohistochemistry (IHC)
Left brain hemispheres were collected and fixed in 4% PFA for 5 days.
Following two successive changes of 30% sucrose and embedding the brains in
15% gelatin blocks, the tissues were serially sectioned into 40µm sections using
a sliding microtome (K. Nagamoto-Combs et al., 2016). To perform
immunostaining against Aβ, antigen retrieval was required using 25% formic acid
(Sigma-Aldrich) for 25 min at room temperature. After at least 30 min blocking
with IHC solution [0.5% bovine serum albumin (BSA, Equitech-Bio, Inc.), 0.1%
Triton X-100 (Sigma-Aldrich), 5% normal goat serum (NGS, Equitech-Bio, Inc.),
and 0.02% Na Azide], brain sections were incubated with primary antibody
β-Amyloid (1:500 dilution, D54D2, rabbit mAb, Cell Signaling Technology, Inc.,
Danvers, MA, USA) at 4°C overnight. On the following day, tissues were
incubated using biotinylated secondary antibody goat anti-rabbit IgG (Vector
Laboratories, Inc., Burlingame, CA, USA) for 2 h. To visualize the antibody
binding, a VECTASTAIN Avidin-Biotin Complex (ABC) kit was used followed by
the Vector VIP Peroxidase (HRP) Substrate kit (SK-4600) (Vector laboratories,
Inc., Burlingame, CA, USA). The brain sections were then imaged using a
Hamamatsu 2.0HT digital slide scanner. To determine the area of the Aβ positive
regions within the hippocampus, hippocampal images (3 sections per mouse;
5 animals per condition; total of 15 hippocampal sections/condition) were
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extracted from the images of the brain sections using image processing tools in
Fiji and Aβ positive regions were outlined using a trainable segmentation
algorithm available as a plugin in Fiji and the total areas of the outlined regions
were measured and expressed as percentages of the area of the hippocampus
sections (Arganda-Carreras et al., 2017). Figures were made using Adobe
Photoshop CS3 software (Adobe Systems, San Jose, CA).
Statistical Analysis
Two-way ANOVA multiple comparisons followed by Uncorrected Fisher’s
LSD tests were performed using GraphPad Prism 8 software to analyze our data,
which are represented as the mean ± SEM. Significance is indicated by P value
measurements with a P < 0.05 considered significant; *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001.
Results
Human Colonic Epithelial Cells Expressed APP
H&E staining demonstrated human normal tissue along with well,
moderately, and poorly differentiated colon tumors in colorectal cancer (Fig V-2A
and B). Immunostaining of the same human normal colon and range of
differentiated tumors demonstrated expression of APP by intestinal epithelial
cells (FigV-2C and D). Our human colon array findings are in line with a report
from Venkataramani et. al which shows robust APP staining in human colon
cancer tissue (Venkataramani et al., 2010). Although this data did not provide
any information regarding processing of APP, it did confirm that APP is

101

Figure V- 2.

Histology and APP immunohistochemistry of human normal
colon and colorectal cancer tissue arrays. Representative H&E
staining of human normal colon and colorectal cancer ranging
from well to poorly differentiated tumors are shown with
A) 5X magnification and B) 20X magnification. Representative
APP immunoreactivity demonstrated APP expression in
epithelial cells in human normal colon tissue and colorectal
cancer tumors shown with C) 5X magnification and D) 20X
magnification. Boxes demarcate areas displayed in higher
magnification images.

expressed by colonic epithelial cells in a fashion independent of healthy or
tumorigenic condition.
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AOM/DSS Exposure Reduced Overall Survival Rates and Body Weights
Except for Female AppNL-G-F Mice
Survival rates of AOM/DSS treated mice were demonstrated based on
Kaplan-Meier survival curves. On week 2, the survival rate of male AOM/DSS
treated groups decreased to 91%, 40%, and 83% for wild type, App-/-, and
AppNL-G-F mice, respectively. The survival rate of female wild type went from 91%
on week 1 to 73% on week 2.
At the same week, the survival proportion of female App-/- animals reduced
to 82%. However, 100% of the female AppNL-G-F drug treated group survived
throughout the study (Fig. V-3A and B).
The % weight loss were only graphed for mice that survived the whole
procedure. AOM/DSS treatment robustly increased the % weight loss of both
males and females on week 2 compared to their respective vehicle controls
(Table V-3) (Fig V-3C and D). Wild type and AppNL-G-F males, and to a lesser
extent wild type females, did not return to a final body weight similar to their
respective vehicle controls even by week 17. However, there were no significant
differences between the final body weight of App-/- male and female, and AppNL-GF

females starting from weeks 5, 4, and 3 to the end of the study, respectively.

Both genders across genotypes were provided 1.5% DSS dissolved in their
drinking water. However, Table V-2 demonstrates a slightly higher average DSS
consumption in males compared to females. This is likely due to greater body
weight in males versus females resulting in greater consumption. Overall, these
results suggest both sex and genotype differences in response to the AOM/DSS
treatment.
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Figure V- 3.

The survival rate and %body weights were reduced following
AOM/DSS treatment except for AppNL-G-F female mice. KaplanMeier survival curves were generated for A) male and B) female
vehicle or AOM/DSS treated wild type, App-/-, and AppNL-G-F
mice. The percentage of body weight changes was calculated for
17 weeks for C) male and D) female vehicle or survivors of the
AOM/DSS treatment.
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Table V- 3 . The % weight loss changes per week per genotype and gender for 17 weeks.
Male
Week 0: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 2: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 3: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 4: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 5: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 6: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 7: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 8: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 9: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 10: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 11: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 12: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 13: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 14: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 15: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 16: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 17: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 0: App-/- Vehicle vs. App-/- AOM/DSS
Week 2: App-/- Vehicle vs. App-/- AOM/DSS
Week 3: App-/- Vehicle vs. App-/- AOM/DSS
Week 4: App-/- Vehicle vs. App-/- AOM/DSS
Week 5: App-/- Vehicle vs. App-/- AOM/DSS
Week 6: App-/- Vehicle vs. App-/- AOM/DSS
Week 7: App-/- Vehicle vs. App-/- AOM/DSS
Week 8: App-/- Vehicle vs. App-/- AOM/DSS
Week 9: App-/- Vehicle vs. App-/- AOM/DSS
Week 10: App-/- Vehicle vs. App-/- AOM/DSS
Week 11: App-/- Vehicle vs. App-/- AOM/DSS
Week 12: App-/- Vehicle vs. App-/- AOM/DSS
Week 13: App-/- Vehicle vs. App-/- AOM/DSS
Week 14: App-/- Vehicle vs. App-/- AOM/DSS
Week 15: App-/- Vehicle vs. App-/- AOM/DSS
Week 16: App-/- Vehicle vs. App-/- AOM/DSS
Week 17: App-/- Vehicle vs. App-/- AOM/DSS
Week 0: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 2: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 3: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 4: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 5: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 6: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 7: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 8: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 9: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 10: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 11: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 12: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 13: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 14: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 15: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 16: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 17: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
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P Value
>0.05
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
>0.05
<0.0001
<0.0001
<0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
<0.0001
<0.0001
<0.01
<0.05
<0.05
<0.05
<0.01
<0.001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Significant
ns
****
****
****
****
****
****
***
****
****
****
****
****
****
****
****
****
ns
****
****
*
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
****
****
**
*
*
*
**
***
****
****
****
****
****
****
****
****

Female
Week 0: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 2: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 3: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 4: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 5: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 6: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 7: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 8: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 9: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 10: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 11: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 12: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 13: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 14: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 15: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 16: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 17: Wild Type Vehicle vs. Wild Type AOM/DSS
Week 0: App-/- Vehicle vs. App-/- AOM/DSS
Week 2: App-/- Vehicle vs. App-/- AOM/DSS
Week 3: App-/- Vehicle vs. App-/- AOM/DSS
Week 4: App-/- Vehicle vs. App-/- AOM/DSS
Week 5: App-/- Vehicle vs. App-/- AOM/DSS
Week 6: App-/- Vehicle vs. App-/- AOM/DSS
Week 7: App-/- Vehicle vs. App-/- AOM/DSS
Week 8: App-/- Vehicle vs. App-/- AOM/DSS
Week 9: App-/- Vehicle vs. App-/- AOM/DSS
Week 10: App-/- Vehicle vs. App-/- AOM/DSS
Week 11: App-/- Vehicle vs. App-/- AOM/DSS
Week 12: App-/- Vehicle vs. App-/- AOM/DSS
Week 13: App-/- Vehicle vs. App-/- AOM/DSS
Week 14: App-/- Vehicle vs. App-/- AOM/DSS
Week 15: App-/- Vehicle vs. App-/- AOM/DSS
Week 16: App-/- Vehicle vs. App-/- AOM/DSS
Week 17: App-/- Vehicle vs. App-/- AOM/DSS
Week 0: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 2: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 3: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 4: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 5: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 6: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 7: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 8: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 9: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 10: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 11: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 12: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 13: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 14: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 15: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 16: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
Week 17: AppNL-G-F Vehicle vs. AppNL-G-F AOM/DSS
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P Value
>0.05
<0.0001
<0.0001
<0.01
<0.05
>0.05
>0.05
<0.05
<0.05
>0.05
<0.05
<0.05
<0.05
<0.05
>0.05
<0.01
<0.01
>0.05
<0.0001
<0.0001
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
<0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05
>0.05

Significant
ns
****
****
**
*
ns
ns
*
*
ns
*
*
*
*
ns
**
**
ns
****
****
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
*
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns

AOM/DSS Treatment Did Not Induce Colorectal-associated Symptoms
in Female AppNL-G-F Mice
The granulomatous nature of inflammation and extent of anemia induced
by DSS exposure is associated with an increase of colon and spleen weights as
well as shortening of colon length (Chassaing et al., 2014a). On week 17, the
AOM/DSS treated male groups demonstrated a significant decrease in colon
length of wild type mice, an increase in colon weight of App-/- mice, and an
increase in colon and spleen weights of AppNL-G-F mice compared to their
respective controls (Fig. V-4A-C). Colon length and weight were significantly less
in App-/- compared to AppNL-G-F male mice in the AOM/DSS treatment groups.
Colon and spleen weights were significantly higher in AppNL-G-F vs. wild type
males in drug treated groups.
In females, AOM/DSS administration dramatically shortened wild type
colon length and increased wild type and App-/- colon and spleen weights
compared to their vehicle controls (Fig. V-4D-F). Interestingly, colon weight and
length as well as spleen weight of AppNL-G-F mice did not differ due to AOM/DSS
treatment vs. their vehicle group. Female AppNL-G-F colon length was significantly
higher than wild type and App-/- mice in AOM/DSS treated groups. Colon and
spleen weights of wild type females were greater than App-/- and AppNL-G-F
AOM/DSS treated groups. These data suggest increased sex-related CAC
inflammation in AppNL-G-F males compared to females.
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Figure V- 4.

AOM/DSS treatment affected colon and spleen weights and
colon lengths in a sex and genotype-dependent manner. Colon
and spleen weights and colon length were measured from wild
type, App-/-, and AppNL-G-F A-C) male and D-F) female vehicle
and AOM/DSS treated mice to quantify inflammation, *p<0.05, **
p<0.01, ***p<0.001, and ****p<0.0001 (mean ± SEM, n=4-11
animals).

AOM/DSS Administration Produced Various Sex- and Genotype-Dependent
Tumor Numbers and Areas
In males, AppNL-G-F mice (n=5) demonstrated significantly greater tumor
number and area compared to wild types (n=10) and developed more tumors
than the App-/- group (n=4) following AOM/DSS treatment (Fig. V-5A and B). In
contrast, female wild type (n=8) and App-/- (n=9) AOM/DSS treated animals
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Figure V- 5.

AOM/DSS treatment induced tumors in a sex and genotypedependent manner. Tumor number and area were counted and
measured, respectively, from wild type, App-/-, and AppNL-G-F
male and female mice to indicate the extent of disease induced
by AOM/DSS exposure across strain and sex, *p<0.05, **
p<0.01, ***p<0.001, and ****p<0.0001 (mean ± SEM, n=4-11
animals).
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displayed significantly more tumors with greater tumor areas compared to AppNLG-F

mice (n=10) with only 20% tumor development (Fig. V-5C and D). The

number of tumors in female wild types was significantly more than App-/- group
tumors. Tumorigenesis was not observed in male and female vehicle treated
groups. These data indicate an association of sex and APP
expression/processing with progression of tumors in the AOM/DSS murine
model.
Histologic Severity of Tumorigenesis and Inflammation Induced by
AOM/DSS Treatment Were Sex- and APP-Associated
AOM/DSS exposure induced moderate to severe inflammation in wild
type, App-/-, and AppNL-G-F males (Fig. V-6A-E). Both App-/-, and AppNL-G-F
AOM/DSS treated groups demonstrated significantly greater mucosal
hyperplasia, neoplastic transformation, and subsequent total histology score
compared to wild type mice. Except minimal incidental inflammation observed in
the male wild type vehicle group, none of controls revealed colonic pathology
(Fig. V-6A-E).
Inversely, the majority of AppNL-G-F females, except one, did not develop
robust inflammation following AOM/DSS administration compared to the wild type
and App-/- groups (Fig. V-7A-E). However, wild type and App-/- females showed
drastically greater inflammation, mucosal hyperplasia, neoplastic transformation,
and total histology scoring compared to the AppNL-G-F female drug treated group
(Fig. V-7A-E). Taken together, these observations suggest different genotype
and sex susceptibility toward CAC in which males resulted in worse colonic
pathology in App-/- survivors and AppNL-G-F compared to wild type mice and in
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females led to poor tumorigenesis in AppNL-G-F compared to App-/- and wild type
groups. Surprisingly, AppNL-G-F males developed adenocarcinoma whereas
females demonstrated normal to mild colonic histology.

Figure V- 6.

The extent of tumorigenesis following AOM/DSS treatment in
male mice was genotype dependent. A) Representative H&E
staining of Swiss-rolls of normal colon and AOM/DSS-induced
CAC are shown with 4X magnification. Histological lesions of
wild type, App-/-, and AppNL-G-F animal colons are shown by
scoring B) inflammation, C) mucosal hyperplasia, D) neoplastic
transformation, and E) total histology, *p<0.05, ** p<0.01,
***p<0.001, and ****p<0.0001 (mean ± SEM, n=4 animals).
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Figure V- 7.

AppNL-G-F females were resistant to CAC induced by AOM/DSS
administration compared to wild type and App-/- counterparts.
A) Representative H&E staining of normal and cancerous colons
are shown with 4X magnification. Colon B) inflammation,
C) mucosal hyperplasia, and D) neoplastic transformation were
scored individually, and E) total histology was calculated,
*p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 (mean ± SEM,
n=4 animals).
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CAC Induced by AOM/DSS Administration Exacerbated Aβ Accumulation in
AppNL-G-F Males with No Effect on Females
The primary goal of the study was to determine whether wild type or
mutant AβPP expression altered the colonic tumorigenic response following
AOM/DSS treatment. However, based upon our prior findings that DSS-induced
colitis-like conditions exacerbated brain Aβ pathology, we asked whether the
AOM/DSS induced tumorigenesis might have a similar effect on the brain. The
impact of CAC induced by AOM/DSS on Aβ accumulation in the brain was
assessed by immunohistochemistry. Aβ plaque quantitation in the hippocampus
showed a significant increase of amyloid plaque load in AppNL-G-F AOM/DSS
treated males compared to their respective vehicle group (Fig. V-8A-B).
However, hippocampal Aβ deposition did not change due to drug
treatment in female AppNL-G-F mice compared to their vehicle group (Fig. V-8CD). As expected, both male and female wild type and App-/- mice brains were
devoid of detectable Aβ aggregation. These data confirmed a direct impact of gut
inflammation and tumorigenesis on exacerbation of Aβ pathology in an AD
mouse model. More importantly, it paralleled our intestinal findings in that male
AppNL-G-F mice responded more robustly to AOM/DSS treatment overall with
regard to gut inflammation, tumorigenesis, and brain plaque deposition.
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Figure V- 8.

Aβ deposition was exacerbated in AppNL-G-F male but not female
hippocampi following CAC induced by AOM/DSS exposure. A,
C) Immunohistochemistry was performed on serial brain sections
(40µm) from male and female AOM/DSS treated wild type, App-/, and AppNL-G-F mice as well as vehicles using anti-Aβ antibody.
Representative images are shown with 4X magnification. B, D)
%mean area was measured using 3 different sizes of
hippocampus sections/mouse/condition, ***p<0.001 and
****p<0.0001 (mean ± SEM, n=5 animals).
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CHAPTER VI
DISCUSSION
Study I
IGF-1R Inhibitor Ameliorated Neuroinflammation in an
Alzheimer’s Disease Transgenic Mouse Model
We observed that reversible pharmacologic inhibition of IGF-1R via PPP
reduced insoluble Aβ1-40/42 levels, eotaxin, TNF-α, IL-1α, IL-1β, and IL-10 levels
in temporal cortices of 9-10 month-old AβPP/PS1 mice. This correlated with
decreased protein levels of p-tyrosine, CD68, and microglia phagocytic activity in
the AβPP/PS1 hippocampi as a result of the IGF-1R inhibitor treatment.
Previously, we demonstrated higher levels of IGF-1 in parietal cortex but
not hippocampus of AβPP/PS1 mice at 6 months of age compared to WT mice
(Kendra L. Puig et al., 2016). The present data also revealed no significant
differences in IGF-1 levels between these two genotypes in the temporal cortices
of 9-10-month-old mice before or after the drug exposure (Fig. II-8). Consistent
with our prior work, this suggests that there is heterogeneity of IGF-1 levels in
brain regions. Besides local expression of IGF-1, roughly 95% of this protein is
transported from the liver to the brain crossing the blood-brain barrier suggesting
there may be some regional selectivity of import (E. Carro, Nuñez, Busiguina, &
Torres-Aleman, 2000; Yamamoto & Murphy, 1995). Also, higher levels of serum
IGF-1 have been demonstrated both in 3xTg-AD mice and AD patients compared
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to controls (Parrella et al., 2013; Vardy et al., 2007). Thus, in order to investigate
the levels of local brain IGF-1, the circulating IGF-1 and its transport into the
brain must be considered in future work (M. M. Adams et al., 2009).
Nevertheless, our data demonstrate that transient pharmacologic inhibition of the
brain IGF-1R is a feasible strategy, in addition to genetic elimination of IGF-1 or
its receptor, to study the effect of this growth factor in the CNS.
Much of the mechanistic effects of IGF-1R signaling inhibition related to
AD using inhibitors or genetic deletion of the receptor rely on in vitro studies. For
example, like IGF-1, Aβ1-42 monomers reportedly activate the IGF1R/PI3K/Akt/CREB pathway in mature cultures of pure cortical neurons after a 30
min exposure. CREB (cyclic adenosine monophosphate response element
binding protein) activation induces expression of BDNF (brain-derived
neurotropic factor) involved in memory formation. PPP and LY294002, the PI3K
inhibitor, reverse this effect (Zimbone et al., 2018). Similarly, activated IGF-1R,
due Aβ1-42 monomer stimulation, promotes glucose uptake in cultured neurons at
physiological concentrations. This is also inhibited by PPP treatment (Giuffrida et
al., 2015). In contrast, Aβ1-42 monomers, under pathological conditions,
accumulate into oligomers leading to neuronal and synaptic loss (Giuffrida et al.,
2015). Even though Aβ oligomers show attenuating effects on active p-CREB
levels, no changes were observed on p-Akt levels in vitro (Zimbone et al., 2018)
indicating direct activation of the IGF-1R pathway via monomeric Aβ1-42. This
suggests that Aβ oligomers may not downregulate p-CREB via inhibiting the IGF1R/Akt signaling pathway since CREB is also activated by other signaling
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pathways (Ortega-Martínez, 2015). In another study, astrocyte-specific IGF-1R
knockout cultures demonstrated increased mitochondrial ROS production, and
diminished Aβ1-42 uptake (Logan et al., 2018). These studies suggest distinct
roles of IGF-1R in different cell types that support both potentiating and
attenuating functions during disease.
Human and AD mouse model studies also demonstrate dichotomous
effects of IGF-1R in AD. Similar to our data, several human and animal AD
studies support an exacerbating role for IGF-1R signaling in AD. For instance,
hyperactivation of the PI3K/Akt/mTOR pathway has been reported in postmortem tissue from the inferior parietal lobe of amnestic mild cognitive
impairment and AD patients compared to controls. Activation of this pathway
leads to protein synthesis/protein homeostasis and downregulation of
autophagy/protein clearance (Tramutola et al., 2015). A decrease in autophagy
function, as a result of PI3K/Akt/mTOR pathway activation, is associated with the
aggregation of Aβ1-42 proteins in the brain (Tramutola et al., 2015). Similarly,
Aβ accumulation upregulates mTOR signaling and pharmacological inhibition of
mTOR with rapamycin decreases Aβ1-42 and tau levels and alleviates cognitive
deficits by promoting autophagy in an AD mouse model (Caccamo, Majumder,
Richardson, Strong, & Oddo, 2010). In another study, a natural plant extract,
curcumin, led to induction of autophagy, inhibition of Aβ production, and cognitive
improvement via attenuating the PI3K/Akt/mTOR pathway in AβPP/PS1 mice (C.
Wang, Zhang, Teng, Zhang, & Li, 2014). Additionally, a beneficial effect of
inhibiting the insulin/IGF-1 signaling cascade via NT219 has been reported in
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nematodes. The inhibitor induced a reduction of p-IGF-1R and degradation of the
insulin receptor substrates 1 and 2 (IRS1/2) leading to the enhanced stress
resistance and protection against Aβ and polyQ40 proteotoxicity, AD and
Huntington’s disease associated proteins, respectively (El-Ami et al., 2014).
However, others have reported beneficial effects of IGF-1R signaling in AD. A
sporadic AD rat model which was developed by intracerebral administration of
streptozotocin (STZ) revealed increased AD characteristics including, p-tau, Aβ42,
and neuroinflammation, and impaired IGF-1R/Akt signaling. However, T3D-959
treatment, an orally active brain-penetrating PPARδ/γ dual nuclear receptor
agonist and a potent insulin sensitizer, ameliorated cognitive deficits and AD
pathological hallmarks via promoted expression of insulin/IGF-1/Akt signaling
proteins in the temporal lobes (de la Monte, Tong, Schiano, & Didsbury, 2017).
Except for the latter study, many investigations of IGF-1R signaling, including our
own, were performed using AβPP/PS1 mice which is a familial AD model that
overexpresses mutant AβPP/PS1. The AβPP/PS1 model demonstrates robust
plaque deposits but no p-tau containing neurofibrillary tangles as a limitation that
may ultimately alter our ability to extrapolate findings to human disease.
It was notable that IGF-1R inhibition demonstrated clear insoluble Aβ1-40/42
attenuating effects but not soluble Aβ changes in our study (Fig. II-2). This is
consistent with results from Gontier and colleagues who generated the ADINKO
model via knocking out the IGF-1R gene in adult neurons of AβPP/PS1 mice by
injecting tamoxifen at 2 months of age. They reported decreased Aβ monomer,
oligomer, insoluble Aβ, and amyloid plaque density correlating with reduction of
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both proteotoxicity and neuronal loss in the forebrain (Gontier et al., 2015).
Interestingly, similar results, including decreased Aβ pathology, were not
observed by ablating the neuronal IGF-1R in 17 month-old AβPP/PS1 (ADINKO)
mice when they had already developed advanced disease symptoms (George et
al., 2017). According to Paranjape and colleagues, soluble Aβ1-42 protofibrils
more rigorously stimulate TNF-α production in primary microglia compared to
Aβ1-40 protofibrils (Paranjape, Gouwens, Osborn, & Nichols, 2012). More
importantly, Aβ1-42 is the more dominant form in plaques due to its higher rate of
fibrillization and insolubility compared to Aβ1-40 (Serrano-Pozo, Frosch, Masliah,
& Hyman, 2011). This suggests that IGF-1R inhibition resulted in the production
of a less immunostimulatory form of Aβ. It is curious that our drug treatment with
the IGF-1R inhibitor decreased insoluble but not soluble levels of Aβ1-40/42. One
possible explanation for this difference in Aβ conformation changes is that fibril
clearance or aggregation are altered by inhibiting IGF-1R. Collectively, these
data illustrate the complexity of IGF-1 and its associated receptor in mediating
changes in the transgenic mice and suggest that anti-amyloid therapeutic
strategies that interfere with IGF-1R signaling may be dependent upon age,
particular cell type, disease state, and even the conformation of Aβ.
Our data also demonstrated an immunomodulatory effect of PPP
treatment via reducing cytokine levels including eotaxin, TNF-α, IL-1α, IL-1β, IL10 in the AβPP/PS1 temporal cortex (Fig. II-7). Elevated levels of eotaxin in the
serum and IL-6, IL-1β, and TNF-α in the cerebrospinal fluid of AD patients have
been reported previously (Blum-Degen et al., 1995; C. Choi et al., 2008;
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Tarkowski et al., 2003). TNF-α, IL-6, and IL-1β levels were also elevated in
plasma of AD patients compared to control subjects in a meta-analysis study
(Swardfager et al., 2010). Moreover, an IL-1α allele 2 polymorphism is
associated with AD development (Du et al., 2000). These reports indicate that
rodent cytokine changes are relevant to the human disease. These immune
regulatory consequences of IGF-1R inhibition parallel findings from others
demonstrating that 16 months of rapamycin administration decreases
hippocampal IL-1β levels correlating with improved learning and memory
(Majumder et al., 2012). In addition, intracerebroventricular injection of
Aβ oligomers, which induces synaptic and cognitive deficits, failed to induce
neuroinflammation and behavioral dysfunction in neuronal IGF-1R knockout mice
(Clarke et al., 2015; Ferreira, Lourenco, Oliveira, & De Felice, 2015; George et
al., 2017; Lesné et al., 2013).
Our strategy for assessing beneficial effects of attenuated IGF-1R
signaling relied on use of PPP, a reversible, selective inhibitor of the IGF-1R
which preferentially targets the PI3K/Akt pathway (D. Vasilcanu et al., 2004). In
addition, this drug is reported to be brain penetrant although our current study did
not quantify this (Yin et al., 2010). PPP treatment is expected to inhibit
phosphorylation of IGF-1R, but not other tyrosine kinase receptors (Girnita et al.,
2004; R. Vasilcanu et al., 2008). PI3K/Akt/mTOR is considered a primary
signaling response of the IGF-1R (Gontier et al., 2015) and therefore a likely
target for modulating and assessing IGF-1R effects in the brain. Indeed, elevated
mTOR signaling has been reported in the 3xTg AD mice at 6 and 12 months of
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age as well as in AD brains (Caccamo et al., 2010; Oddo, 2012; Pei & Hugon,
2008; Tramutola et al., 2015). Consistent with this, higher levels of
phosphorylated Akt in 6-month-old AβPP/PS1 mice compared to controls have
also been reported. However, 17 month-old AβPP/PS1 mice demonstrate lower
levels of Akt phosphorylation compared to their respective controls (George et
al., 2017). Similarly, we also observed increased levels of phosphorylated IGF1R, but not Akt, in 9-10-month-old AβPP/PS1 mice compared to the WT controls
(Fig. II-5). Collectively, these results suggest that IGF-1R signaling responses
may vary depending upon the age of the mice or the transgenic mouse line. In
addition, the level of signaling response changes may be downstream of receptor
phosphorylation itself.
Despite the clear brain effects of PPP administration, this was not
reflected in any changes in levels of either IGF-1R or Akt phosphorylation in the
drug treated hippocampi via western blot analysis (Fig. II-5). This is expected
based upon the short half-life of PPP (2-4 hours) and is the most likely
explanation for this lack of effect since we collected mouse brains one day after
the last injection of the inhibitor and acute drug effects on phosphorylation events
were no longer present (Economou et al., 2008). Indeed, this encouraging
transient effect provided some assurance that IGF-1R inhibition can be targeted
in the brain without long-term consequences of impairing receptor signaling.
However, our global assessment of tyrosine kinase-based signaling responses
via anti-p-tyrosine western blotting demonstrated a significant decrease in protein
levels in the drug treated mouse brains suggesting that some persistent signaling
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responses were still decreased even one day after drug treatment that will need
to be identified (Fig. II-5). Also, in support of the rapid, transient nature of IGF-1R
signaling, Ito and colleagues detected a rapid increase of IGF-1R
phosphorylation 30 min after Aβ1-42 oligomer microinjection into the hippocampus
of an AD mouse model. Although long-term effects of IGF-1R phosphorylation
were not monitored in this study, co-microinjection of PPP resulted in an
attenuated increase of p75 neurotrophin receptor levels 24 h after injection in a
prior work consistent with our findings of drug-dependent attenuation of protein
changes (Ito et al., 2012). In accordance with the idea that drug treatmentdependent effects on acute IGF-1R-related signaling responses are transiently
detectable, rapamycin treatment did not change the levels of total or
phosphorylated mTOR although it did decrease levels of Aβ42 and deposition, tau
pathology, and early learning and memory impairments in 3xTg AD mice
(Caccamo et al., 2010). By contrast, neuronal knock-out IGF-1R AD (ADINKO)
mice demonstrated decreased cortical phosphorylated Akt/Akt (Gontier et al.,
2015). This difference might be due to the long-term and irreversible inactivation
of the IGF-1R response in that mouse model. Collectively, these findings support
the idea that although pharmacologic manipulation of the IGF-1R signaling
response results in significant changes in the brain, assessment of receptor
signaling responses likely depends upon treatment times and the analysis
method. We employed a short-term treatment of 7 days with a minimal dosage of
1mg/kg to exert reversible effects on IGF-1R signaling responsible for beneficial
effects on Aβ levels and inflammatory state in these AD mice. This concentration
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is far less than prior work which used 10-20mg/kg in mice to exert brain effects
on central control of body temperature or glioma growth and produced no lasting
effects on brain p-IGF-1R levels (Cintron-Colon et al., 2017; Yin et al., 2010).
However, our preliminary data supported the efficacy of acute PPP injection at
1mg/kg dosage 15 min after drug administration (Fig. II-1).
We observed a somewhat cell selective effect of attenuated microgliosis
while astrogliosis remained unchanged in the hippocampus of the male
AβPP/PS1 drug treated group compared to vehicle controls (Fig. II-3,5).
Interestingly, others have found similar results of attenuated microglial
accumulation in the cortex and hippocampus of both genders of ADINKO mice
(Gontier et al., 2015). Moreover, higher astrogliosis was reported in the
hippocampus of female ADINKO mice without any changes in female cortex or
male ADINKO hippocampus and cortex versus controls (Gontier et al., 2015).
These results suggest that genetic as well as pharmacological inactivation of
IGF-1R correlates with attenuated microgliosis without a clear linkage to
associated changes in astrogliosis in different AD mouse models.
Perhaps this is not surprising given the fact that microglial function from
altered phagocytosis to cytokine secretion is associated with the progression of
AD (McQuade & Blurton-Jones, 2019). According to our data, PPP administration
attenuated microgliosis and total p-tyrosine levels which was in correlation with
our previous report (Dhawan et al., 2012). This suggests that immunomodulatory
effects of IGF-1R inhibition in the brain may be mediated through altered
microglial phenotype (Fig. II-5). Surprisingly, however, we did not observe any
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effects of IGF-1R stimulation on microglial phagocytic ability for either Aβ or
bacterial bioparticles (Fig. II-10A). However, IGF-1 stimulation did alter Aβstimulated TNF-α secretion from microglia in vitro suggesting that IGF-1 does
alter Aβ-mediated microglial secretion phenotype (Fig. II-10B). Interestingly, we
also observed that co-stimulation with Aβ and IGF-1 increased mitochondrial
dehydrogenase activity assessed via MTT reduction assay (Fig. II-10C). Our data
indicate that IGF-1 stimulation of Aβ plaque-associated microglia in vivo may
indeed be contributing to microglial reactivity.
Our in vivo study suggests that short-term pharmacologic inhibition of the
IGF-1R can decrease AD-related pathological features including Aβ deposition,
microgliosis, and select cytokine changes. Importantly, this effect appears to be
partially selective for microglia compared to astrocytes and insoluble Aβ
compared to soluble. However, since the IGF-1R is key to biological pathways
involved in the aging process and age-related diseases, additional work is
needed to investigate the effect of chronic administration of PPP or other
pharmacologic IGF-1R inhibitors on the progression of AD. Furthermore, more
comprehensive assessment of disease phenotype including behavioral outcomes
corresponding with complete evaluation of pharmacological suppression of IGF1R signaling will be needed to better validate the IGF-1R as a valid long-term
target for disease attenuation.
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Study II
Gut Inflammation Induced by Dextran Sulfate Sodium Exacerbated
Aβ Plaque Deposition in the AppNL-G-F Mouse Model of
Alzheimer’s Disease
To the best of our knowledge, this is the first study investigating a direct
contribution of intestinal inflammation to Aβ plaque levels and reactive gliosis
using the AppNL-G-F transgenic mouse model. We have previously reported that
colonic inflammation correlates with brain Aβ plaque deposition starting at
3 months of age in AppNL-G-F mice and increased pro-inflammatory markers and
macrophages in the ileums of AppNL-G-F and APP/PS1 mice compared to controls
(G. D. Manocha et al., 2019; K. L. Puig et al., 2015). In this study, we report that
chronic intestinal disruption induced by two cycles of DSS exposure resulted in
moderate colitis-like symptoms in wild type and AD animals with significant motor
dysfunction in AppNL-G-F mice. Damage to colonic integrity led to an increase in
Aβ plaque load in hippocampi and temporal cortices along with a decrease in
microglial phagocytic phenotype in AppNL-G-F mice maintained during the healing
or recovery phase after injury. Taken together, these findings suggest that basal
intestinal inflammation, which has been reported in our previous studies,
exacerbated by DSS administration in AD animals can propagate to the brain
and promote Aβ plaque formation likely via a reduction in Aβ clearance and to
some extent increased APP processing.
It is important to point out that we used the DSS-induced colitis model as a
general means of driving intestinal inflammation and not to indicate that IBD, per
se, influences the risk of AD. DSS, is a negatively charged sulfated
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polysaccharide that induces intestinal inflammation by disrupting intestinal
epithelial integrity to increase colonic permeability leading to translocation of gut
microbiota and their metabolites from the lumen into underlying tissue and
infiltration of leukocytes into the lamina propria and submucosa followed by the
production of pro-inflammatory cytokines (Chassaing et al., 2014b). Colonic
disruption induced by DSS results in diarrhea, weight loss, and gross rectal
bleeding, pathology similar to individuals with ulcerative colitis (Okayasu et al.,
1990; Perše & Cerar, 2012). This is a controllable, reproducible, simple, and
rapid method to induce inflammation and provides the opportunity to study the
resolution of inflammation compared to the bacterial induction or transgenic
models, in which colonic inflammation continues without amelioration. Although
DSS studies are often performed in younger mice from 6-18 weeks of age
(Bercik et al., 2011; Di Martino et al., 2016; Emge et al., 2016; Han et al., 2018;
Hassan et al., 2014; Jirkof et al., 2013; M. Kumar, Kissoon-Singh, Coria, Moreau,
& Chadee, 2017; Loren et al., 2017; F. Lu, Fernandes, & Davis, 2010; Mar et al.,
2014; Mitrovic, Shahbazian, Bock, Pabst, & Holzer, 2010; Villaran et al., 2010;
Zonis et al., 2015) we elected to use older mice at 24-40 weeks of age to allow
us to examine AD-related brain changes. In spite of this older age paradigm,
symptomatic parameters, colon histology (erosions and goblet cell loss) and
changes in immunohistochemistry staining (tight junction protein levels and
CD68) as well as lipocalin-2 ELISA assessments demonstrated successful
colitis-like pathology induction in both genotypes in line with other reports
(Chassaing et al., 2012; Emge et al., 2016; Perše & Cerar, 2012; Reichmann et
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al., 2015; S. L. Wang et al., 2019). According to Snider and colleagues, mice are
expected to recover to their initial weight during the course of recovery (Snider et
al., 2016). However, neither wild type nor AppNL-G-F animals completely recovered
after ending the second cycle of DSS treatment in our paradigm. This could be
due to treating mice with DSS at an older age in our study. However, similar to
our data, Chassaing and colleagues reported that weight loss and loose stool
continued for 5 weeks after DSS removal in mice with a C57BL/6 background
(Chassaing et al., 2014b).
It has been reported that wild type animals with DSS-induced colitis show
prolonged immobility, abnormal behavioral stress responses, memory
impairment, and alterations in expression levels of genes involved in the limbic
system (Emge et al., 2016; Reichmann et al., 2015; Reichmann, Painsipp, &
Holzer, 2013). Indeed, we expected to observe exacerbation of memory deficits,
at least, in our DSS treated mice. Our OF and CM data revealed that DSS
administration did persistently decrease mobility of AppNL-G-F mice compared to
their controls assessed during the second resolution phase, 12 days post
exposure. However, our OF and CM tests did not demonstrate any anxiety-like or
memory deficits due to DSS treatment. It could be that only transient behavioral
deficits were induced by DSS-induced inflammation which normalized during the
interval phase. Consistent with our data, previous studies reported exacerbation
of anxiety-like behavior or memory dysfunction when assessed during active
colonic inflammation, 0-3 days after DSS cessation. These behavioral changes
resolved during the recovery phase even though the colitis-like symptoms,
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including shortened colon length, colonic histological damages, and the
increased myeloperoxidase (MPO) activity, were still present (Emge et al., 2016;
Jang et al., 2018; Reichmann et al., 2015). For example, wild type mice treated
with 3% DSS for 5 days demonstrated recognition memory deficits and anxietylike behavior 3 days post exposure, during active disease, tested by novel object
recognition task and light/dark box test, respectively. However, behavior was no
longer different 9 days post DSS treatment compared to controls (Emge et al.,
2016). Similarly, impaired learning and memory in the Y-maze and passive
avoidance tasks were resolved, during recovery of inflammation, 15 days after
colitis induced by 2.5% 2,4,6-trinitrobenzenesulfonic acid (TNBS) for 5 days
(Jang et al., 2018). Taken together, these data indicate that disruption of gut
barrier integrity induced by chemicals results in a transient anxiety-like condition
and memory dysfunction which returns to basal levels during resolving of
inflammation. Nevertheless, the prolonged immobility observed in our study may
represent gut inflammation-associated major depression which can be measured
by the tail suspension and forced swimming tests (Cryan, Mombereau, &
Vassout, 2005; Petit-Demouliere, Chenu, & Bourin, 2005). More importantly, the
long-lasting attenuation in locomotor activity could be attributed to brain
responses due to intestinal dysbiosis in AppNL-G-F versus wild type mice basally
or resulting from DSS treatment (Håkansson et al., 2015; Shen et al., 2017; Vogt
et al., 2017; S. L. Wang et al., 2019; L. Zhang et al., 2017). Additional behavioral
assessments and microbiome studies may help to further understand the
differences observed.
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In correlation with the intestinal inflammation induced by the DSS
treatment, we observed a modest increase in select brain proinflammatory
markers, Cox-2 and VCAM-1, in AppNL-G-F mice compared to wild type mice.
However, we observed no DSS-induced increase in brain cytokines levels in
either line. Similarly, there were no increases in markers of gliosis but instead a
significant decrease in a microglial phagocytic marker, CD68. It was surprising
that we did not observe an increase in either GFAP or Iba-1 immunoreactivity but
instead a decrease in CD68 immunoreactivity in the DSS treated AppNL-G-F mice
in spite of a slight but significant increase in Aβ levels and Aβ plaque deposition
in the treated mice. It is unknown why the increase in plaque load is
disconnected from these common markers of gliosis. Nevertheless, the
decreased CD68 immunoreactivity indicates a potential change in Aβ phagocytic
ability which correlates with the increased plaque deposition observed. A more
extensive profiling of microglial phenotype, in particular, is clearly required
following DSS treatments.
Although our hypothesis was supported that intestinal dysfunction can
alter brain inflammatory changes, it is not clear why the AppNL-G-F mice were
selectively vulnerable. One possibility for this bias in effect could be that the
AppNL-G-F mice have elevated basal inflammation that exacerbates select
consequences of DSS exposure in some fashion. Our prior work did observe
increased age-associated intestinal inflammation in AppNL-G-F mice compared to
controls (G. D. Manocha et al., 2019). Consistent with this idea, a recent study
showed that systemic inflammation attenuated microglial clearance capacity
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leading to a permanent increase in Aβ deposition starting on day 2 post LPS
challenge in aged APP/PS1 mice (Tejera et al., 2019). These results are in
concordance with a human postmortem brain study which reported decreased
CD68 and increased protein levels of IL-6 in AD patients with terminal systemic
infection at the time of death compared to AD individuals without systemic
infection (Rakic et al., 2018).
Alternatively, it could be that both lines experienced transient brain
changes that resolved to varying degrees during the recovery phase. This idea is
consistent with prior work demonstrating that systemic inflammation induced by
injection of the bacterial cell wall component, LPS, transiently increased CD68
immunoreactivity 2 days after challenge followed by resolution 10 days post
exposure in mice 15 month of age, with no effect on 5 month-old, wild type mice.
Likewise, a transient increase in GFAP immunoreactivity as well as brain and
peripheral pro-inflammatory cytokine levels (IL-1β and TNF-α), which peaked 2
days after induction of peripheral inflammation, returned back to basal levels 10
days post treatment in wild type mice with both ages. (Tejera et al., 2019).
Elevated levels of hippocampal TNF-α also resolved 15 days after colitis induced
by TNBS in another study (Jang et al., 2018). This suggests that the moderate
inflammatory challenge model we employed may lead to transient brain
inflammatory changes that could be exacerbated by prolonged or multiple
challenges as might be experienced during a lifetime of intestinal disease.
One possibility for the elevated Aβ levels and plaque deposition observed
following DSS treatment is due to exposure to bacteria or bacterial products
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through the disrupted colonic epithelium. It is feasible that Aβ production is
upregulated in response to the bacterial extravasation since numerous studies
have reported the anti-microbial property of Aβ (D. K. Kumar et al., 2016; Moir,
Lathe, & Tanzi, 2018; Soscia et al., 2010). For example, Aβ overexpression
protects female 5XFAD transgenic mice from meningitis induced by an intracerebral injection of Salmonella Typhimurium (D. K. Kumar et al., 2016).
Similarly, a transgenic C. elegans model of AD (GMC101) was also protected
against Candida albicans infection due to Aβ expression in vitro and in vivo in the
same study (D. K. Kumar et al., 2016). Although viral related, Aβ accumulation
has been detected in herpes simplex virus type 1 (HSV1)-infected cells as well
as mouse brains. This data correlated with localization of HSV1 DNA in amyloid
plaques of AD brains (Wozniak, Mee, & Itzhaki, 2009). The virus also
upregulates BACE1 expression suggesting that HSV1 induces Aβ processing
and plaque formation (Ill-Raga et al., 2011; Itzhaki, 2018). Similar observations
have been made following intranasal infection with a respiratory pathogen,
Chlamydia pneumoniae, which induced amyloid deposition in non-transgenic
BALB/c mouse brains with increasing density, size, and number of deposits as
infection progressed (Little, Hammond, MacIntyre, Balin, & Appelt, 2004).
Likewise, systemic lipopolysaccharide (LPS) administration induces Aβ
formation, neuroinflammation, and cognitive deficit in animal models (J. W. Lee
et al., 2008; Zhao et al., 2019).
In addition to the possibility that elevated brain Aβ levels in DSS treated
mice is a general anti-microbial response, there is a particular relationship
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between intestinal bacterial changes and AD. For instance, Polysaccharide A
(PSA) produced by Bacteroidetes species Bacteroides fragilis, a gram-negative
anaerobic commensal bacteria in the human GI tract, protects against central
nervous system demyelination and inflammation. However, in its enterotoxigenic
capacity, Bacteroides fragilis might be associated with inflammatory bowel
disease and neuro-inflammatory signaling in AD due to secretion of toxins,
including LPSs and toxic proteolytic peptides (Fathi & Wu, 2016; Lukiw, 2016; K.
J. Rhee et al., 2009; Y. Wang et al., 2014). In addition, higher levels of the gut
microbiota-derived metabolite, trimethylamine N-oxide (TMAO), have been
detected in cerebrospinal fluid of individuals with mild cognitive impairment (MCI)
and AD compared to healthy controls (D. Li et al., 2018; Vogt et al., 2018). AD
patients demonstrate decreased microbial diversity and altered gut microbiota
composition compared to controls, including decreased Firmicutes and
Actinobacteria, particularly the Bifidobacterium genus, as well as increased
Bacteroidetes (Vogt et al., 2017). Also, Odoribacter and Helicobacter abundance
at the genus level, which belong to the Bacteroidetes and Proteobacteria phylum,
respectively, are elevated in APP/PS1 transgenic mice compared to wild type
controls (Shen et al., 2017). Increased Proteobacteria and decreased short-chain
fatty acid (SCFA) levels in APP/PS1 mice compared to wild type control have
also been reported (L. Zhang et al., 2017). Interestingly, similar to AD animal
models and humans, it has been reported that TNBS and DSS-induced colonic
inflammation also cause dysbiosis via increasing gram-negative bacteria, such
as Proteobacteria and Bacteroidetes, and decreasing gram-positive bacteria,
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including Firmicutes (Emge et al., 2016; Jang et al., 2018; S. L. Wang et al.,
2019). In addition, long-term combinational antibiotic cocktail treatments reduce
Aβ plaque deposition, decrease numbers of plaque-localized astrocytes (GFAP)
and microglia (Iba-1), and change microglial morphology to a ramified state in
male APP/PS1 mice (Minter et al., 2016). Germ-free APP transgenic mice show
decreased brain Aβ deposition compared to their counterparts with intact gut
microbiota, while this effect is reversed after colonization of the germ free mice
with microbiota from intact AD mice (Harach et al., 2017). More importantly, gut
microbiota and their metabolites, such as SCFAs, modulate microglia maturation,
differentiation, and function (Erny et al., 2015). These data collectively suggest
the involvement of specific intestinal bacteria or their metabolites in the
progression of AD. Future efforts to determine intestinal microbiome changes
and subsequent communication mechanisms to the brain may elucidate how the
DSS-induced inflammation potentiated plaque deposition.
Taken together, our study suggests that short-term peripheral
inflammation induced by DSS treatment was sufficient to induce long-lasting
changes in brain Aβ levels, plaque deposition, and microglial phenotype.
Extensive immune, neuronal, and glial characterization of temporal brain
changes during repeated intestinal inflammatory bouts early and later in life to
model different onsets and time courses of human intestinal disease will provide
information regarding whether intestinal inflammation can alter the rate or
severity of AD in mice. In addition, identifying the cross-talk mechanisms of
communicating intestinal dysfunction to the brain whether it is microbiome,
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endocrine, immune, or nervous related may identify means of attenuating the
peripheral contribution to AD.
Study III
Effect of Alzheimer’s Disease Associated APP Mutations on the
Progression of Colorectal Cancer Induced by AOM/DSS in Mice
In our previous investigations, we reported a contribution of colitis-like
inflammation induced by DSS on exacerbation of Aβ plaque load in AppNL-G-F
males suggesting that peripheral inflammatory changes communicate to the
brain to exacerbate AD. In this study, we report that prolonged colonic
inflammation induced by AOM/DSS administration developed genotype
dependent CAC symptomatic parameters, including decreased colon length,
increased spleen and colon weights, increased tumor number and area as well
as colonic histology in a fashion significantly greater in AppNL-G-F males vs.
respective females and wild type males. Autosomal dominant AD mutations in
APP resulted in exacerbated brain plaque load, worsened intestinal inflammation,
and increased colonic tumorigenesis in male mice compared to wild types due to
AOM/DSS treatment while these same mutations provided protection against
intestinal inflammation and tumor development with no change in brain plaques
in female AppNL-G-F mice. The survival rate in male wild type mice was greater
than wild type females, whereas AOM/DSS treated App-/- and AppNL-G-F males
showed lower survival rate than their respective females.
In order to recapitulate human-like colorectal cancer in mice and
investigate its correlation with expression of wild type or mutant AβPP in both
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sexes, an AOM/DSS combined treatment was utilized to induce the CAC due to
its high reproducibility, simplicity, potency, and affordability. This model provides
a shorter latency period compared to only AOM or DSS treated models. In this
paradigm, the procarcinogen AOM, a metabolite of 1,2 dimethylhydrazine (DMH),
reaches the liver via the bloodstream following i.p. injection. Hydroxylation of
AOM by cytochromes P450 in the liver leads to formation of
methylazoxymethanol (MAM), a macromolecule alkylating agent. MAM is
transported to the colon via bile and targets the colonic mucosa to induce an O6methyl-deoxyguanosine (O6mG) → A transition mutation in DNA with a ∼12 h
half-life. In concert with this, DSS damages the colonic epithelial monolayer lining
to induce intestinal inflammation (Chassaing et al., 2014a; De Robertis et al.,
2011; Neufert, Becker, & Neurath, 2007; Parang, Barrett, & Williams, 2016;
Rosenberg, Giardina, & Tanaka, 2009).
Interestingly, the incidence rate of dementia, including AD, is greater in
women than men (Beam et al., 2018; Mielke, 2018; Vina & Lloret, 2010). In
contrast, colorectal cancer incidence and mortality is higher in men compared to
women (Douaiher et al., 2017; White et al., 2018). Similarly, a meta-analysis of
population-based cohort studies reports a greater risk of ulcerative colitisassociate colorectal cancer in males (Jess, Rungoe, & Peyrin-Biroulet, 2012). It
is important to note that there is also a sex difference in colonic tumor location.
For instance, women are at higher risk of developing right-sided (proximal) colon
cancer. While, left-sided (distal) colon cancer is common in men (S. E. Kim et al.,
2015). AOM/DSS treatment predominantly develops tumor in the distal part of
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colon and mimics colorectal cancer in men (De Robertis et al., 2011; Parang et
al., 2016). This may partially explain the sex differences we observed although
not the increased severity observed in male AppNL-G-F mice compared to wild
types males or the reduced severity of female AppNL-G-F mice compared to wild
type females.
Different sex and genotype susceptibility to AOM/DSS treatment has been
observed in other reports. Similar to our AppNL-G-F data, microscopic and
histological examinations demonstrate more severe CAC in AOM/DSS male ICR
mice, including earlier tumor incidence and significantly higher total tumor
number, compared to females (S. M. Lee et al., 2016). Specific STAT1 deletion
in intestinal epithelial cells (STAT1∆IEC) is associated with increased intestinal
tumor load in males but not females with colitis-associated colorectal cancer
following AOM/DSS exposure demonstrating a male-specific tumor suppressive
function of epithelial STAT1 in mice and human colorectal cancer (Crnčec et al.,
2018). Comparing AppNL-G-F males with females and AppNL-G-F females versus
wild type females may indicate a female-selective tumor suppressor function of
AD mutant APP. Further work is needed to characterize and manipulate
processing of APP into Aβ, N-terminal, and AICD fragments in both sexes of
AppNL-G-F mice to determine whether mutant expression alone or proteolytic
fragments of APP are involved in the increased susceptibility (males) or
protection (females) against CAC compared to wild type mice.
One possibility for explaining the sex differences in susceptibility to
AOM/DSS treatment is simply differences in sex hormone function. For example,
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early administration of estradiol to male ICR AOM/DSS treated mice alleviates
inflammation and prevents from colorectal cancer (Son et al., 2019). AOM/DSS
treatment in ovariectomized female ICR mice leads to the increased proximal
colon tumor number and incidence rate compared to the control AOM/DSS
female group. 17β-estradiol (E2) administration following ovariectomy
significantly suppresses the increased colonic tumorigenesis. However, mice
ovariectomy exerts no effect on tumorigenesis in the distal colon in comparison
with the AOM/DSS control female group (Song et al., 2019). The androgen
receptor (AR) is a fundamental transcription factor involved in the
pathophysiology of prostate and breast cancers, in which sex hormones play
pivotal roles. Interestingly, it controls target genes which promote tumor growth
or proliferation activity, including APP, via androgen-dependent AR-binding sites
(ARBS) (Takagi et al., 2013; Takayama et al., 2009). This suggests that APP
may be an androgen-dependent growth factor. It will be of interest to determine
whether sex hormone receptor signaling is responsible for the differences we
observed when comparing male and female AppNL-G-F mice and well as wild type
versus AppNL-G-F male and female mice.
App-/- males and females followed a different pattern compared to AppNL-GF and

wild type mice regarding % weight loss. Despite developing tumors, both

genders regained weight back to their vehicle control levels. Also, App-/- males
demonstrated higher susceptibility and death rate following drug treatment
compared to their female counterparts. 6 out 10 App-/- male mice died during
treatment with the 4 remaining animals demonstrating colonic tumors. App-/- mice
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are viable and fertile and demonstrate reactive gliosis as well as a 15-20%
decrease in weight compared to their age-matched wild-type controls (Zheng et
al., 1995). This basal difference perhaps reflects a growth factor property of APP
in vivo (Rossjohn et al., 1999). Indeed, APP knockdown via lentiviral shRNA
expression results in cell motility and growth prevention by inducing apoptosis in
breast cancer cells in vitro and in a xenograft mouse model (S. Lim et al., 2014).
Similarly, inhibition of APP expression and subsequent sAPP generation using
antisense techniques robustly reduces thyrotropin-induced thyroid epithelial cell
proliferation (Pietrzik et al., 1998). However, our App-/- mouse data suggests that
genetic ablation of the APP gene did not protect against colonic tumorigenesis in
males or females but instead conferred some selective mortality risk to male
mice.
This apparent discrepancy with a mitogenic role for APP and sAPPα could
be due to developmental compensation in the App-/- mice. It is important to note
that both APP and APP-like protein 2 (APLP2) are ubiquitously expressed
throughout the body, including colon tissue (K. L. Puig & Combs, 2013; van der
Kant & Goldstein, 2015; W. Wu et al., 2012). Double knockouts for App-/-/APLP2/-

or APLP1-/-/APLP2-/-, and knockouts for App-/-/APLP1-/-/APLP2+/- mice

demonstrate early postnatal lethality. However, App-/-/APLP1-/- mice are viable
(Heber et al., 2000; von Koch et al., 1997). These results indicate that either APP
or APLP2 is required for mouse viability and APLP2 could take over the function
of APP (Zheng & Koo, 2006) in the intestines of App-/- mice which might explain
the lack of protection against cancer development. APLP2 lacks the Aβ region
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but undergoes proteolysis similar to APP. Cleavage of APLP2 via α-, β-, and γsecretases leads to production of sAPLP2, a membrane-bound C-terminal
fragment, p3/ Aβ-like fragments, and an APP-like intracellular domain (ALID
similar to AICD) allowing this protein to possibly compensate for genetic deletion
of App. (Eggert et al., 2004; Endres, Postina, Schroeder, Mueller, & Fahrenholz,
2005; Pastorino et al., 2004; Scheinfeld, Ghersi, Laky, Fowlkes, & D'Adamio,
2002; Walsh et al., 2003).
Although the focus of this study was to assess the effects of mutant APP
expression on tumorigenesis, our prior work demonstrated that prolonged colonic
inflammation in a DSS-induced colitis-like paradigm was sufficient to exacerbate
brain amyloidosis in male mice. We observed as similar effect in this study in
which robust tumorigenesis and neoplasm in AppNL-G-F male mice resulted in a
significant increase in Aβ plaque load. This potentiation of plaque load was not
observed in female AppNL-G-F mice consistent with their overall minimal change in
intestinal inflammation and tumor count. Therefore, besides the primary
conclusion of mutant APP expression altering tumorigenic susceptibility in a sexdependent manner, we also confirmed that robust intestinal inflammatory
conditions are sufficient to communicate to the brain to worsen brain pathology
associated with AD. Future work with an inflammatory stimulus equivalent in both
male and female intestines will better determine whether there is a sex-bias in
gut-brain communication. In addition, the mechanisms by which intestinal
dysfunction communicates to the brain will need to be determined. For example,
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the well-described brain-gut-microbiota axis is a likely component of this
communication mechanism (Martin, Osadchiy, Kalani, & Mayer, 2018).
Taken together, we report that prolonged colonic inflammation resulting
from AOM/DSS-induced CAC in AppNL-G-F males, but not females, increased
Aβ deposition and tumorigenic potential. However, mutant APP expression in
AppNL-G-F females provided a sex-dependent colonic tumor suppressor function
which exerted no impact on Aβ aggregation compared to AppNL-G-F vehicle
females.
Limitations and Future Directions of Work Presented in This Dissertation
The research presented in this dissertation indicates a significant role of
peripheral manipulation, more specifically intestinal inflammation, on the
development and progression of AD. The reciprocal role of mutant APP in colonic
tumorigenesis is also addressed in a sex-dependent manner in an AD mouse
model. There are a few limitations of the studies presented in this dissertation as
well as some logical next steps for future work.
The AD transgenic models containing familial mutations (AβPP/PS1 and
AppNL-G-F) enabled us to study the role of an IGF-1R inhibitor as well as colitislike and CAC pathologies on an early onset familial AD paradigm. These familial
cases of AD represent a minority of human cases and are characterized by
robust Aβ production atypical of the more common late onset sporadic form of
AD. In order to assess the role of peripheral manipulation and gut inflammation
on late onset AD, we could in the future use a B6.129S2-Tg(APP)8.9Btla/J
mouse provided from the Jackson laboratory. This transgenic mouse model
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carries a humanized APP gene without mutations which would provide an
opportunity to study induction of APP amyloidogenic processing and Aβ
aggregation in the brain as a direct consequence of disrupting the intestinal
barrier. Mice carrying a humanized APOE4 (heterozygous or homozygous) could
be employed for a similar purpose of trying to better model human late onset
disease, since APOE4 represents a significant risk for late onset disease. These
transgenic mice cannot develop an AD phenotype by themselves (Onos, Sukoff
Rizzo, Howell, & Sasner, 2016) and require crossing to the B6.129S2Tg(APP)8.9Btla/J mouse in order for the combined cross to develop AD-like
pathology.
To further study the effect of PPP on AD pathology improvement, chronic
administration and a higher dosage of PPP (20mg/kg, twice a day,
intraperitoneally) at least for 3 weeks could be performed in future investigations
(Menu et al., 2006). In addition, behavioral changes correlating with the brain
pathological alterations should be assessed. As with any pharmacologic
intervention, the appropriate ADMET and PK/PD studies are also needed for
PPP to optimize a long-term treatment strategy that would better assess its
efficacy for treating AD in the mice.
To better assess the impact of DSS-induced colitis-like pathology on the
progression of AD, a younger AD mouse model (1-2 month old) with less or no
Aβ deposition could be utilized in future work. Sensitive, movement-limited more
appropriate behavioral tests, including the step-down and fear conditioning
assessments, could also be performed right after ending the last DSS exposure
141

to minimize any confounds from lack of mobility and to capture impairment prior
to recovery (Bercik et al., 2011; Bravo et al., 2011). In addition, we could
consider an intervention to attenuate the colitis-induced exacerbation of disease.
For example, Natalizumab or Adalimumab are attractive therapeutic possibilities
which might be able to attenuate the peripheral immune dysfunction and exert
benefits in the brain without a necessity to penetrate blood-brain barrier (BBB).
Natalizumab (Tysabri), a humanized monoclonal antibody against α4 integrin
subunit, prevents cell migration across the BBB and gastrointestinal tracts via
blocking the interaction of α4β1 and VCAM-1 as well as α4β7 and MAdCAM-1,
respectively. Adalimumab is a human monoclonal anti-TNF-α antibody that
currently is used for inflammatory bowel disease (Paramsothy, Rosenstein,
Mehandru, & Colombel, 2018). Indeed, prior work from our group has already
demonstrated a therapeutic benefit in APP/PS1 mice using tail vein delivery of
anti-α4β7 antibody (G. Manocha, Ghatak, Puig, & Combs, 2018).
Although the sex differences in tumorigenic susceptibility in male versus
female AppNL-G-F mice implies a sex hormone difference, the fact that both sexes
differed significantly from sex matched wild type mice suggests that the APP
mutations also had a role in tumor growth. In order to better understand this
complexity, future work to begin dissecting apart mutant APP-associated colonic
tumorigenesis could employ RNAseq or microarray regional analysis from colons
and even brains to better understand the sex and genotype susceptibilities. The
impact of APP or its processed fragments on tumorigenesis could also be
evaluated using other human cancer models, including breast and prostate
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cancers to determine whether the changes we observed are colon cancer
specific. In addition, β-, α-, and γ-secretase inhibitors, including verubescestat,
batimastat, GI254023X, and semagascestat, could be administered as
intervention therapeutics to assess whether preventing or promoting
amyloidogenic processing in a sex-selective fashion alters colon tumor
development. This could offer the exciting possibility of repositioning drugs
developed for treating APP processing in AD to find new use in cancer biology. In
addition, to assess whether mutant APP expression modulates cell proliferative
activity and apoptosis in the colon, 5-bromo-2′-deoxyuridine (BrdU) and terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining can be
performed, respectively, in a future work to compare to histologic, biochemical,
and molecular biology changes.
Summary Conclusions
The work presented in this study suggests a significant contribution of
peripheral intestinal dysfunction, more specifically colitis-like and CAC
pathophysiology, on exacerbation of AD characterized by increased Aβ
deposition.
Interestingly, mutant APP expression in the AppNL-G-F AD mouse model
modulates colonic inflammation and tumorigenesis and subsequent brain effects
in a genotype and sex-dependent manner. Mutant APP appears to provide a
specific tumor suppressor function in the colons of the female AppNL-G-F mice
compared to both wild type females and AppNL-G-F males. However, mutant APP
expression exacerbates both colonic inflammation and neoplasm in AppNL-G-F
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male mice compared to wild type males which communicates to the brain to
significantly increase Aβ plaque load.
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